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Many Asian countries have experienced an increasing incidence and disease 
burden associated with coronary heart diseases (CHD) in the past decades in 
parallel with changes in people’s diet. Dietary fatty acids have been implicated in 
the etiology of CHD, but the effects of specific fatty acids are remarkably 
different, with many remaining uncertainties. In addition, few population-based 
studies have evaluated the involvement of potential biological mediators in the 
relationship between fatty acids and CHD risk. 
This thesis aims to provide a better understanding of the roles of cooking oils, 
dietary and plasma fatty acids, and oxidized metabolites of fatty acids in relation 
to various established cardiovascular risk factors and the risk of CHD.  
Consumption of palm oil has been increasing in many emerging Asian economies 
including India and China. In Study I, a systematic review was conducted to 
evaluate published evidence from clinical trials on the effect of palm oil 
consumption on blood lipids. Based on the pooled estimates from meta-analysis, 
palm oil significantly increased LDL-cholesterol as compared with vegetable oils 
low in saturated fat. This effect was observed in randomized trials, but not in non-
randomized trials. As compared with trans-fat containing oils, palm oil 
significantly increased HDL-cholesterol. No significant difference in blood lipids 
was found between palm oil and animal fat. 
In Study II and III, a nested case-control study was established within the 
Singapore Chinese Health Study, with 744 incident acute myocardial infarction 
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(AMI) cases and 744 matched controls. In Study II, an automated clustering 
approach was used to group 19 plasma fatty acids and 12 oxylipins based on their 
inter-correlations and to assess their prospective relation with AMI risk. Long-
chain n-3 fatty acids and stearic acid were inversely associated with AMI risk, 
while arachidonic acid was directly associated with AMI risk. These associations 
were not attenuated after adjustment for oxylipins. We also observed a significant 
inverse association between thromboxane B2, an arachidonic acid-derived 
oxylipin, and AMI risk. 
Study III assessed the association between dietary and plasma omega-3 
polyunsaturated fatty acids (n-3 PUFAs) and risk of AMI, and the possible 
mediation of this association by established cardiovascular risk factors. Higher 
plasma alpha-linolenic acid (ALA) was significantly associated with lower blood 
pressure and lower LDL-cholesterol, but also with lower HDL-cholesterol and 
higher triglycerides. We observed an inverse association between plasma ALA 
and AMI risk, and this association became substantially weaker after adjustment 
for LDL-cholesterol and stronger after adjustment for HDL-cholesterol. In 
contrast, plasma and dietary long-chain n-3 PUFAs were consistently associated 
with a lower AMI risk, and the association was not substantially attenuated by 
adjustment for cardiovascular risk factors. 
These findings suggest important etiological roles of fatty acids in the 
development of CHD. These effects may be partially explained by their impact on 
established cardiovascular risk factors, but not by the set of oxylipins we 
measured. To achieve a reduced cardiovascular burden, it is advisable to replace 
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palm oil with vegetable oils low in saturated fat and maintain adequate intake of 
ALA as well as long-chain n-3 fatty acids.   
 x 
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CHAPTER 1. INTRODUCTION 
1.1 CORONARY HEART DISEASE 
Coronary heart disease (CHD), also known as ischemic heart disease or coronary 
artery disease, is the narrowing of coronary arteries which supply blood and 
oxygen to the heart muscle (1). This is usually caused by atherosclerosis, where 
atheromatous plaques consisting of white blood cells, fatty material and other 
substances accumulate on the artery wall. As a result, blood flow to the heart 
muscle could be reduced or even stopped, leading to symptoms including angina 
pectoris (chest pain), nonfatal myocardial infarction, and coronary death (2). 
CHD is the most common sub-group of diseases among cardiovascular diseases. 
It is the leading cause of global mortality, responsible for 14.8% of deaths 
worldwide (Figure 1-1) (3). CHD has been the most common reason of death in 
many developed countries (4), and its incidence in many Asian countries is also 
increasing rapidly in recent decades, in parallel with changes in diet and other 
lifestyle risk factors (5, 6). In Singapore, cardiovascular diseases are the leading 
cause of morbidity and mortality, responsible for an estimated 20% of disability 
adjusted life years (Figure 1-2) and 34% of mortality (7). 
Major risk factors of CHD include smoking, obesity, physical activity, diet, blood 
cholesterol, blood pressure, and fasting blood glucose (8). Many of these risk 
factors are highly modifiable, as is also observed in the differences in CHD rates 
between countries, over time, and in migrating populations (9, 10). Knowledge on 
specific dietary factors can facilitate the maintenance and the adoption of 
Chapter 1. Introduction 
- 2 - 
 
healthful dietary intakes, which could improve the underlying pathophysiology of 
CHD. 
 
Figure 1-1. Percentage of global years of life lost (YLLs) by cause from 1990 
to 2010 
Source: Lozano R, et al. The Lancet 2012;380(9859):2095-128 (11) 
 
Dietary changes in the general population could be achieved by changing food 
choices of the public through dietary advice or by industrial modification of foods. 
The former approach has been successful in various instances, e.g. polyunsatured 
fat intakes have increased markedly in the U.S. (12). Netherlands has used the 
latter approach to remove trans-fat from margarine, which was estimated to have 
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prevented ten thousands of deaths due to CHD (13). The U.S. Food and Drug 
Administration will also remove partially hydrogenated oils from food 
manufacturing in three years (14). Among the dietary factors related to 
cardiovascular risk, dietary fatty acids have been implicated in the etiology of 
CHD particularly. For both effective recommendations to the public and industrial 
modification of foods, detailed knowledge on the role of specific fatty acids is 
needed. 
 
Figure 1-2. Distribution of disability-adjusted life years (DALYs) in 
Singapore by broad disease cause groups, 2010 
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1.2 DIET-HEART HYPOTHESIS 
According to the classic diet-heart hypothesis (Figure 1-3), increased intake of 
dietary saturated fat and cholesterol and decreased intake of polyunsaturated fat 
could increase serum cholesterol levels, which results in atheromatous plaques 
deposition along the inner wall of blood vessels. The accumulation of such 
plaques in the coronary arteries narrows the arteries, reduces blood flow, and 
eventually leads to myocardial infarction (15).  
 
Figure 1-3. The classic diet-heart hypothesis 
Source: Gordon T. Am J Epidemiol 1988;127(2):220-5 (15) 
1.2.1 Animal studies and descriptive studies 
This diet-heart hypothesis originates from animal studies in the 1930s which 
observed arterial lesions caused by dietary cholesterol through elevated blood 
cholesterol (16, 17). Evidence from ecologic studies and migrant studies was also 
consistent with this hypothesis. The seven countries study observed a strong 
correlation between intake of saturated fat and CHD (9). The Ni-Hon-San 
migration study observed increased intake of saturated fat in parallel with 
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increased CHD incidence among Japanese migrants in Hawaii and San Francisco 
than native Japanese populations (10). These descriptive studies provided 
preliminary evidence that CHD rates differ dramatically among populations, and 
such differences are primarily due to environmental rather than genetic factors. 
However, such observations could not draw causal conclusions as they could not 
exclude potential confounding by other dietary and lifestyle risk factors. 
1.2.2 Studies of serum cholesterol as intermediary marker of CHD 
The relationship between diet and serum cholesterol as an intermediary disease 
marker was evaluated in many early randomized controlled feeding trials, and the 
findings were summarized as prediction equation of serum total cholesterol based 
on intake of saturated fat, polyunsaturated fat, and cholesterol (18, 19). The more 
recent feeding studies changed the focus of surrogate endpoint after the 
recognition of different sub-components of serum total cholesterol, including the 
detrimental ones in low-density lipoprotein (LDL) and very low-density 
lipoprotein (VLDL) as well as the beneficial ones in high-density lipoprotein 
(HDL). Observations from these studies were summarized in new prediction 
equations: substitution of carbohydrates by saturated fat increases both LDL- and 
HDL-cholesterol in proportion and decreases triglycerides; substitution of 
carbohydrates or saturated fat by monounsaturated fat or polyunsaturated fat 
decreases LDL-cholesterol and triglycerides, and increases HDL-cholesterol (20, 
21). 
Studies relating serum total cholesterol to the risk of CHD, e.g. the Multiple Risk 
Factor Intervention Trial (22), have unanimously observed a monotonic 
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correlation with no threshold over a wide range of cholesterol levels. Using 
cholesterol fractions in LDL and HDL provides an even stronger prediction of 
CHD risk than total cholesterol, with the strongest predictor being the ratio of 
total-to-HDL cholesterol (23). The causal link between LDL-cholesterol and CHD 
risk is further strengthened by clinical trials with LDL-cholesterol-lowering drugs. 
In contrast, possibly because of the complicated heterogeneity of HDL particles, 
most of the pharmacological agents targeting to raise HDL-cholesterol was not 
effective in reducing cardiovascular events (24). 
1.2.3 Case-control and cohort studies of diet and CHD 
The use of serum cholesterol as intermediary marker for risk of CHD cannot 
make firm conclusions about the influence of dietary fats on CHD, as the etiology 
of CHD is not limited to elevated blood cholesterol but also involves other 
complex pathways. Therefore, evidence from case-control and cohort studies on 
the direct relation between diet and CHD is necessary.  
Inconsistent findings were reported from case-control studies, and careful 
interpretation should be taken due to potential selection bias and recall bias. One 
example of a carefully conducted case-control study was in Costa Rica, in which 
biases were mitigated through wide coverage of hospitalization healthcare, regular 
census, high participation rate, and objective assessment of adipose tissue fatty 
acids. This study has observed positive association between trans-fatty acids and 
myocardial infarction, and inverse association for alpha-linolenic acid (25, 26). 
Use of palm oil for cooking was associated with higher myocardial infarction risk 
(27), which will be discussed in Chapter 3. 
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Prospective cohort studies could eliminate selection and recall biases, and are 
expected to produce consistent findings. Evidence from previous cohort studies 
has been summarized in a meta-analysis, which found a positive association 
between saturated fat and CHD when compared with polyunsaturated fat, but not 
when compared with carbohydrates (28). Two more recent meta-analyses 
observed no association between saturated fat and CHD, but the source of 
replacement energy is not specified (29, 30). Overall, most studies provide 
general support for the classic diet-heart hypothesis, but the evidence for specific 
dietary fatty acids is weak and inconsistent. Modest associations were expected 
due to limited variations in dietary intake of many nutrients within a study 
population. Furthermore, many of the existing cohort studies are opportunistic 
analyses of data not intended for investigation of the diet-heart relationship, and 
are thus subject to many potential limitations, including small study size, dietary 
assessment at a single point in time, and inadequate adjustment for confounding 
by total energy intake and other dietary factors. An example of well-conducted 
large cohort study with repeated dietary measures and appropriate energy 
adjustment is the Nurses’ Health Study. This study observed that when compared 
with carbohydrates, trans-fatty acids were strongly associated with CHD risk; 
saturated fat was weakly and insignificantly associated with CHD risk; 
monounsaturated fat was modestly associated with a lower risk of CHD; and 
polyunsaturated fat was substantially associated with a lower risk of CHD (31).  
In summary, a large sample size is necessary to quantify the diet-heart relation in 
cohort studies. Available evidence suggests that the association between saturated 
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fat and CHD risk is likely to vary depending on what is being replaced: 
replacement of saturated fat with sugars and refined carbohydrates, unlike 
replacement with polyunsaturated fat, is not likely to be beneficial. 
1.2.4 Studies using biomarkers of fatty acids intake and CHD risk 
Biochemical analyses of fatty acids in plasma lipid fractions, platelet or red cell 
membranes, or subcutaneous fat were used as markers of dietary fat intake in 
some observational studies.  
Some ecologic, cross-sectional, and case-control studies found lower levels of 
adipose tissue linoleic acid to be associated with higher risk of CHD (32-34), but 
no consistent relationships were observed in studies using plasma or cell 
membrane markers (35-41). A prospective nested case-control analysis showed 
low content of linoleic and most polyunsaturated fatty acids and high levels of 
palmitic and stearic acids in the serum phospholipids, but not in cholesteryl ester 
or triglyceride fraction, were predictive of fatal CHD (42). A meta-analysis of 
observational studies using circulating fatty acid biomarkers observed inverse 
associations between long-chain omega-3 polyunsaturated fatty acids and 
coronary outcomes, but no significant associations for omega-6 polyunsaturated 
fatty acids (30). 
Several limitations may influence the interpretation of studies using tissue fatty 
acid markers, including relatively small study size, possible reverse causation by 
acute events in case-control designs, and factors affecting tissue levels of fatty 
acids other than dietary intake, e.g., individual differences in absorption, 
metabolism, selective tissue incorporation, and endogenous production. In general, 
Chapter 1. Introduction 
- 9 - 
 
fatty acids that cannot be synthesized by humans may provide better markers of 
diet. 
1.2.5 Clinical trials of diet modifications to prevent CHD 
Two general strategies were used in dietary interventions to prevent CHD in 
clinical trials: 1) replacing saturated fat by polyunsaturated fat; 2) replacing 
saturated fat by carbohydrates. Early trials conducted among institutionalized men 
observed promising effect of diet changes on reducing CHD risk (43, 44). Later, 
two larger trials evaluated the effect on CHD rates in free-living individuals by 
combined intervention of dietary modification together with simultaneous 
reduction of other risk factors, e.g. smoking cessation. One trial observed 
significantly reduced serum cholesterol, nonfatal and fatal CHD in the 
intervention group (45), while the other did not (46). The contrast between the 
two studies is likely to be because the former study excluded men with high 
serum cholesterol levels who are less likely to be responsive to diet. In general, 
the statistical power to detect a significant difference could be increased by 
selecting a population susceptible to the intervention.  
Dietary change trials have also been conducted among people with existing CHD 
(47-57). A general observation is that overall fat reduction had minimal effect on 
serum total cholesterol levels or CHD incidence, while substitution of unsaturated 
for saturated fat reduced both serum total cholesterol levels and CHD incidence 
(58). In particular, the Lyon Heart Study trial observed that compared with CHD 
patients who consumed a typical American Heart Association diet with overall fat 
reduction, patients who consumed a Mediterranean diet with high 
Chapter 1. Introduction 
- 10 - 
 
monounsaturated fat intake and supplemented alpha-linolenic acid had 
significantly reduced rates of CHD recurrence (49). More recently, a primary 
prevention trial found Mediterranean diet with either olive oil or nuts 
supplementation was effective to reduce CHD events compared with a low-fat 
diet (59).  
1.2.6 Summary and critiques of diet-heart hypothesis 
A large body of indirect evidence provides general support for the diet-heart 
hypothesis. Serum LDL-cholesterol is causally related to risk of CHD, and a 
reduction in serum LDL-cholesterol levels by diet modification and other 
interventions could reduce the incidence of CHD. However, there are limitations 
to the original over-simplified hypothesis. 
First, the total serum cholesterol level does not represent the complete effect of 
blood lipids on risk of CHD. Finer subdivisions of serum cholesterol have been 
identified which are differentially related to CHD risk: the well-established 
fractionation of HDL, LDL and VLDL cholesterols; HDL could be further 
fractionated into HDL-2 and HDL-3; the serum lipid particles could also be 
characterized based on their apolipoproteins (60). The serum level as well as the 
oxidative susceptibility of LDL particles could both affect its atherogenic property. 
Therefore, the anti-oxidant content of dietary oils, e.g. vitamin E in many 
vegetable oils, could influence atherogenesis in addition to the fatty acid 
composition (61). Besides the LDL-cholesterol pathway, dietary lipids may 
increase atherogenesis and CHD incidence through post-prandial elevations in 
triglycerides and chylomicrons (62). 
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Second, serum total cholesterol does not represent the full effect of diet on blood 
lipids. Besides dietary lipids, other aspects of diet such as alcohol intake and total 
energy balance could affect serum cholesterol levels, particularly HDL-
cholesterols (63). Also, blood cholesterol responses of individuals differ 
substantially in response to changes in dietary lipids, and this variability is largely 
genetic (64). A fully developed diet-heart hypothesis needs to include interactions 
with genetic predispositions to hypercholesterolemia and CHD. 
Third, atherosclerosis and progressive coronary narrowing do not fully represent 
the pathophysiology of myocardial infarction. Dietary lipids could influence 
platelet aggregation (65), cardiac arrhythmias (66), and possibly other pathways, 
which together with changes in serum lipids could change risk of CHD. 
Furthermore, saturated fat and polyunsaturated fat have frequently been treated as 
homogenous entities, but evidence for the importance of their heterogeneity has 
become clearer with deeper investigations. The chemical structure, finer divisions, 
and the physiological effects of fatty acids will be discussed in section 1.3.  
 
1.3 FATTY ACIDS 
1.3.1 Chemistry of fatty acids 
Fatty acids are a group of molecules with a carboxyl group attached to one end of 
a long aliphatic tail (carbon-chain). They are named and categorized according to 
the number of carbon atoms in the aliphatic tail, the number of double bonds, and 
the position and the stereo-configuration of the double bonds (Figure 1-4). These 
differences in chemical structure could result in remarkably different biological 
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effects, and the type of fatty acids may matter more than the total amount of fat 
(58). For example, as discussed in section 1.2, polyunsaturated fat lowers blood 
cholesterol as compared with saturated fat. Among the saturated fats, the shorter-
chain myristic acid (14:0) is more deleterious than the longer-chain palmitic acid 
(16:0) and stearic acid (18:0) (67). Also, with different position of the first double 
bond in the aliphatic tail, omega-3 and omega-6 polyunsaturated fatty acids have 
distinct physiologic effects (68, 69). Unsaturated fatty acids whose double bonds 
are in the trans-configuration are associated with an adverse lipid profile and 
higher CHD risk compared to their counterparts with cis-configured double bond 
(70). Besides these more established associations, the role of certain specific fatty 
acids in the etiology of CHD remains unclear and is of great research interest. The 
following sections will discuss some examples of fatty acids relevant to later 
chapters of this thesis and their physiological effects on the cardiovascular system. 
 
Figure 1-4. Structures of cis, trans, and saturated 18-carbon fatty acids 
Source: Ovesen L, Leth T. Nutrition & Food Science 1995;95(3):16-9 (71) 
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1.3.2 Long-chain omega-3 fatty acids 
Prospective studies found that regular consumption of fish, the major dietary 
source of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs), is 
associated with a lower risk of CHD mortality (72-74). The two major dietary 
long-chain n-3 PUFAs, eicosapentaenoic acid [EPA, 20:5 (n-3)] and 
docosahexaenoic acid [DHA, 22:6 (n-3)], have been shown to reduce serum 
triglycerides (75), prevent ventricular fibrillation (66), and reduce blood pressure 
(76) and platelet aggregation (77). Dietary and circulating long-chain n-3 PUFAs 
were inversely associated with fatal and nonfatal CHD in large prospective 
studies (74, 78). In some clinical trials long-chain n-3 PUFAs administration 
reduced total mortality and CHD incidence (79, 80), but other trials did not 
suggest beneficial effects (81). The results from such supplementation trials are 
likely to vary depending on the general intake level of fish in the study population. 
Meta-analyses of intervention trials and prospective studies showed a stronger 
suggestion of protect effect by long-chain n-3 PUFAs on cardiovascular death, but 
less so on total mortality or nonfatal cardiac events (82-85). 
1.3.3 Alpha-linolenic acid 
The benefits of long-chain n-3 PUFAs in reducing cardiac deaths are well 
supported, but the availability of fish is limited in many regions of the world (86). 
Therefore, whether the plant-derived 18-carbon n-3 PUFA, alpha-linolenic acid 
[ALA, 18:3 (n-3)], has similar benefits in reducing cardiovascular disease is 
important. ALA may serve as the precursor of EPA and DHA in human body, and 
it also may influence CHD risk independent of the formation of long-chain n-3 
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PUFAs (87). The relationship between ALA and CHD risk has been examined in 
fewer studies than long-chain n-3 PUFAs, and findings were not consistent. Some 
epidemiological studies, including studies of fatty acid biomarkers, supported a 
beneficial effect of ALA intake on nonfatal or fatal CHD, particularly sudden 
death (25, 88-91), whereas others suggested no or even detrimental effects (92, 
93). Evidence for the effects of ALA on conventional cardiovascular risk factors 
has also been mixed and controversial (94), with possible beneficial effects on 
platelet function, arterial compliance, and arrhythmia (95). 
1.3.4 Omega-6 fatty acids 
Omega-6 polyunsaturated fatty acids (n-6 PUFAs) are fatty acids whose first 
carbon-carbon double bond from the methyl end is located at the sixth carbon 
atom. Dietary n-6 PUFAs are mainly found in nuts and vegetable oils, and in 
lesser amount in poultry. Meta-analyses have showed lower cardiovascular risk 
associated with higher consumption of n-6 PUFAs (28, 96). Yet, there have been 
concerns about intake of linoleic acid [LA, 18:2 (n-6)], the major dietary n-6 
PUFA, as it may be endogenously converted to arachidonic acid [AA, 20:4 (n-6)], 
and AA may have pro-inflammatory and pro-thrombotic potential through 
synthesis of oxidized metabolites named oxylipins (97-99). In addition, there may 
be interactions between the intakes of shorter-chain n-6 and n-3 PUFAs because 
they compete for the same enzymes for elongation and desaturation in human 
body (100). Specifically, higher intake of LA may lead to greater use of these 
enzymes and a reduced formation of DHA and EPA from ALA and thus reduce 
the beneficial effect of ALA. This phenomenon has widely led to 
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recommendations to increase the n-3 to n-6 fatty acid ratio by decreasing n-6 
PUFAs intake, although the empirical evidence for this recommendation is 
limited (101).  
1.3.5 Trans-fatty acids 
Trans-fatty acids are unsaturated fatty acids with double bonds in the trans-
position instead of the cis-position. Trans-fat is generated from the partial 
hydrogenation process of unsaturated fatty acids in food industry to improve the 
shelf life and texture of foods, and it is also present in natural foods from 
ruminant sources. Artificial trans-fatty acids increase LDL-cholesterol and 
decrease HDL-cholesterol, and thus have a particularly detrimental effect on the 
total-to-HDL cholesterol ratio (21, 70); trans-fatty acids may also result in 
increased lipoprotein-(a) and triglyceride concentrations, inflammation, and 
endothelial dysfunction (70); large prospective studies have also shown trans-
fatty acid intakes and biomarkers were associated with a higher risk of CHD (26, 
102, 103). Governments in several countries have taken action in restricting or 
removing trans-fat from food industry (13, 14). It has been suggested to replace 
partially hydrogenated fats in the food supply with natural saturated fats, e.g. 
palm oil, to reduce trans-fat intakes while maintaining the sensory characteristics 
of foods (104). This possibility will be discussed further in Chapter 3. 
1.3.6 Interactions between fatty acids 
Different fatty acids could interact with each other in addition to their individual 
effects. For instance, intake of ALA may be more beneficial in persons with lower 
intakes of long-chain n-3 PUFAs (105). Trans-fatty acids can interfere with the 
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synthesis of long-chain n-3 PUFAs from ALA through inhibition of delta-6-
desaturase (106). Also, there may be interactions between the intakes of shorter 
chain n-6 and n-3 PUFAs as discussed in section 1.3.4. 
1.3.7 Self-reported intakes versus biomarkers of fatty acids 
Diet is usually assessed through administration of food frequency questionnaires 
(FFQ), dietary records, or 24-hour recalls. The collected data is then used to 
calculate nutrient intakes including fatty acids with a nutrient composition 
database. The study of major food sources of fatty acids such as different cooking 
oils incorporates all the different fatty acids and non-lipid compounds in these oils 
and provides highly valuable information about whole foods. In addition, studies 
on intakes could be translated into dietary recommendations directly. 
Alternatively, biochemical analyses of fatty acids in plasma lipid fractions, 
platelet or red cell membranes, or subcutaneous fat could be used as markers of 
dietary fatty acids intake. Compared to self-reported intakes, biomarkers are less 
prone to be affected by reporting errors or limitations of nutrient composition 
databases, and can reflect exposure levels at tissues taking into account variations 
in absorption and metabolism. As endogenous production could also influence 
tissue fatty acids levels, fatty acids that cannot be synthesized by humans may 
provide better markers of diet, e.g. odd-chain fatty acids and trans-fatty acids. In 
comparison, for fatty acids which could be produced in human body, direct 
dietary assessment may provide a more accurate assessment of intake levels. For 
example, palmitic acid (16:0) could be produced from excess carbohydrates in a 
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process called fatty acid synthesis, which makes tissue palmitic acid an 
inappropriate marker for dietary palmitic acid intake.  
Clearly, both reported intakes of fatty acids and food sources and biomarkers of 
fatty acids contribute valuable complementarily information. In this thesis, we 
used self-reported dietary intakes as well as measured plasma fatty acids which 
are well established biomarkers of fatty acid intake (107). 
1.3.8 Dietary fatty acids in Asian context 
Studies on dietary fatty acids and CHD have predominantly been conducted in 
western populations, and data in Asian populations are sparse. In Asian diets, 
fatty acids are from different food sources, and the typical range of fatty acid 
intakes is markedly different as compared with western diets (108, 109). This 
provides a unique opportunity for research in Singapore to add to knowledge on 
dietary fatty acids and CHD risk. First, the variation of certain fatty acid intakes 
will be substantially larger in Singapore than in western populations: for example, 
variation in long-chain n-3 fatty acids will be large as high fish consumption is 
common. Second, it will be easier to separate the effects of specific fatty acids 
that are highly correlated in western populations. For instance, sub-types of 
saturated fats are highly correlated in western populations because of shared food 
sources such as red meats, but are mainly from cooking oils in Singapore that 
have a large variety in content of these fatty acids. In addition, a study in Asia will 
be more directly applicable to Asian populations with similar genetic and 
environmental characteristics. 
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To bridge these gaps in knowledge, we have established one of the largest studies 
of CHD in Asia with detailed data on dietary intakes, biochemical intermediates, 
and virtually complete follow-up with rigorous confirmation of incident CHD. A 
detailed description of the study design is described in Chapters 4 & 5. 
 
1.4 OXYLIPINS 
1.4.1 Physiological role of eicosanoids and other oxylipins 
Polyunsaturated fatty acids (PUFAs) could be oxidized into a variety of 
metabolites named oxylipins through specific enzymatic reactions or auto-
oxidation. Eicosanoids are a group of such oxylipins derived from fatty acids with 
20-carbon chain. These include subclasses prostaglandins, prostacyclins, 
thromboxanes and leukotrienes which have been studied extensively. 
Leukotrienes are enzymatically produced through the lipooxygenase (LOX) 
pathway, whereas prostaglandins, prostacyclins, and thromboxanes are produced 
through the cyclooxygenase (COX) pathway (Figure 1-5). Eicosanoids have 
powerful hormone-like effects on inflammation, vasoconstriction and blood 
clotting. For example, thromboxane A2 (TXA2) activates platelets and induces 
vasoconstriction, while prostacyclin (PGI2) has the opposite effects on platelet 
function and vascular tone (110); leukotrienes induce broncho-constriction and 
allergic inflammation of the respiratory system in asthma conditions (111). Many 
popular drugs including aspirin, ibuprofen, and corticosteroids target enzymes 
involved in the production of eicosanoids (112).  
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Figure 1-5. Overview of oxylipins derived from arachidonic acid, linoleic acid, 
and eicosapentaenoic acid: synthesis and physiological effects 
Abbreviations: COX: cyclooxygenase; CYP: cytochrome P450; DHET: 
dihydroxyeicosatrienoic acid; DiHETE: dihydroxy-eicosatetraenoic acid; DiHOME: 
dihydroxy-octadecamonoenoic acid; EEQ: epoxy-eicosatetraenoic acid; EET: 
epoxyeicosatrienoic acid; EpODE: epoxy-octadecadienoic acid; EpOME: epoxy-
octadecamonoenoic acid; HEPE: hydroxy-eicosapentaenoic acid; HETE: 
hydroxyeicosatetraenoic acid; HODE: hydroxy-octadecadienoic acid; HPEPE: 
hydroperoxy-eicosapentaenoic acid; HPODE: hydroperoxy-octadecadienoic acid; KEPE: 
keto-eicosapentaenoic acid; KETE: ketoeicosatetraenoic acid; KODE: keto-
octadecadienoic acid; LOX: lipoxygenase; LT: leukotrienes; PG: prostaglandins (G2, H2, 
D2, E2, F2) / prostacyclins (I2); sEH: soluble epoxide hydrolase; TriHOME: trihydroxy-
octadecamonoenoic acid; TX: thromboxanes; HPETE: hydroperoxy-eicosatetraenoic acid 
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Some more recently found subclasses of oxylipins are formed through the LOX 
and cytochrome P450 (CYP450) pathways (Figure 1-5). In vitro studies have 
shown some of these ‘new’ oxylipins to be involved in pathways affecting 
endothelial cells and platelet adhesivity, influencing inflammation and thrombosis. 
For example, epoxyeicosatrienoic acid (EETs) may be anti-inflammatory by 
decreasing cytokine-induced leukocyte adhesion to vascular endothelium (113); 
the arachidonate monohydroxide 12-hydroxyeicosatetraenoic acid (12-HETE) 
may upregulate platelet adhesivity, while the linoleate monohydroxide 13-
hydroxy-octadecadienoic acid (13-HODE) may suppress endothelial cell 
reactivity to platelets (114). 
1.4.2 Previous studies of oxylipins and CHD 
Changes in dietary fatty acids could change the balance of oxylipins with different 
biological effects by altering the availability of their fatty acid precursors (115-
117). Oxylipins are found in substantial concentrations in plasma, mainly in 
esterified form as part of lipoprotein lipids (118). Lipoproteins allow the transport 
of oxylipins to specific tissues where they can be released by lipoprotein lipase 
and mediate increased expression of inflammatory markers in endothelial cells 
(119). Thus, in addition to changes in membrane function (120) and gene 
regulation (121), circulating oxylipins may represent another important mediating 
pathway for effects of dietary fatty acids on cardiovascular function (77). For 
example, oxylipins derived from n-3 PUFAs could reduce inflammation and 
blood pressure as compared with certain eicosanoids derived from n-6 PUFAs 
(122). This provides a possible mechanistic explanation for several of the 
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beneficial effects of higher intakes of n-3 PUFAs, and also gives rise to concerns 
about n-6 PUFAs who are the biological precursors to a wide range of pro-
inflammatory oxylipins (98). However, recent findings suggest that n-6 PUFAs 
including LA and AA could also be metabolized to a growing list of anti-
inflammatory and anti-thrombotic compounds, including lipoxins and EETs 
(Figure 1-5) (123). 
Epidemiological studies of oxylipins in relation to CHD risk are sparse due to 
lack of accurate methods to measure many of these compounds on a larger scale 
until recently. Several studies have evaluated gene variants known to affect levels 
of oxylipins. For instance, arachidonate epoxides (EETs) are oxylipins with anti-
inflammatory and vasodilatory effects in vitro (113, 124), and these effects are 
regulated by the enzyme soluble epoxide hydrolase (sEH) which hydrolyzes EETs 
to the inactive form of dihydroxyeicosatrienoic acids (DHETs) (125) (Figure 1-5). 
A polymorphism in the sEH gene (EPHX2) resulting in reduced sEH function was 
associated with a 3.5 fold increased risk of coronary heart disease in the ARIC 
study (126). A different sEH gene polymorphism was related to calcified plaque 
size in the CARDIA study (127). These findings are consistent with a murine 
model of atherosclerosis in which a 4-week treatment with a sEH inhibitor 
reduced the size of atherogenic lesions by 50% through increases in linoleate and 
arachidonate epoxides (128). 
A human study involving 30 carotid atherosclerotic plaques reported that 
hydroxyeicosatetraenoic acids (HETEs) were significantly elevated in 
symptomatic plaques as compared with asymptomatic plaques, but EETs and 
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ketoeicosatetraenoic acids (KETEs) were not (129). Of the studied compounds, 9-
HETE was most abundant in plaques. Because this compound cannot be derived 
from known enzymatic reactions, these results suggest that non-enzymatic lipid 
peroxidation may promote plaque instability. Two case-control studies also 
observed elevated levels of plasma HETEs in coronary artery disease cases as 
compared with controls (130, 131). 
These findings suggest a role of oxylipins levels in the etiology of CHD, but 
larger prospective studies with comprehensive assessment of oxylipins are needed 
to provide a greater understanding of the physiological effects of specific fatty 
acid exposures. 
 
1.5 COOKING OILS 
Besides the fatty acids content, other factors could also influence the effect of 
dietary oils on cardiovascular system, including the positional distribution of fatty 
acids in triglycerides, other components of dietary oils, and methods of 
preparation. We will discuss some of these aspects using the example of palm oil.  
Palm oil is derived from the tropical palm plant, Elaeis guineensis, and it 
represents the largest vegetable oil production worldwide. Palm oil contains more 
saturated fat than most other vegetable oils including soybean, canola, and olive 
oils. This leads to the hypothesis that palm oil consumption may have adverse 
effect on blood lipids and increase cardiovascular risk. Evidence from some 
human feeding studies supported this hypothesis, but several counter-arguments 
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have also been proposed such that the effects of palm oil may not be as adverse as 
expected.  
1.5.1 Positional distribution of fatty acids in glycerol structure 
Palm oil and animal fats (e.g. lard, butter) have comparable content of saturated 
fat (mainly palmitic acid, 16:0), but they have distinct positional distribution of 
fatty acids in their triglycerides. Fatty acids in our diet principally exist by 
esterifying with glycerol in the form of mono-, bi- or tri- acylglycerides, with 
triglycerides being the most dominant form. Several animal and human feeding 
studies showed that fatty acids at different positions of triglycerides (Figure 1-6) 
are absorbed and metabolized differently, such that saturated fatty acids at sn-2 
position are better absorbed (132-135). Palm oil, with 70% of its palmitic acid in 
the sn-1 and sn-3 positions of triglycerides, has been hypothesized to be less 
hypercholesterolemic and atherogenic than animal fats whose majority of palmitic 
acid is in the sn-2 position (136, 137). Yet, some other studies observed that the 
cholesterolemic effect of palm oil and lard did not differ significantly (138, 139). 
Thus, more research on the influence of this differential positional distribution 
remains to be determined. 
 
Figure 1-6. The stereochemical configuration of a triglyceride molecule 
showing the sn-numbering of the carbon atoms of glycerol. 
Source: Kubow S. J Nutr Biochem 1996;7(10):530-41 (134) 
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1.5.2 Micro-nutrients in dietary oils 
As mentioned in section 1.2.6, the oxidative susceptibility of LDL particles could 
affect its atherogenic property. Thus, the anti-oxidant content of dietary oils may 
affect atherogenesis in addition to influences by their fatty acid composition (61). 
Crude, unrefined palm oil has the highest content of natural vitamin E, especially 
γ-tocotrienol, among all vegetable oils (up to 800-1000ppm), (140). It is also rich 
in carotenes (500-700ppm), including α-carotene, β-carotene and lycopene (141). 
Most of the vitamin E and carotenes were destroyed during the refining process 
into the typical edible palm oil. In contrary, red palm oil, which is processed from 
crude palm oil under milder conditions, preserves more than 80% of these anti-
oxidants (142), and has been used as alternative medicine to improve vitamin A 
deficiency in certain populations including pregnant women (143). These fat-
soluble natural anti-oxidants may confer cardiovascular benefits on blood lipids 
(144), atherogenesis (145), ischemic injury (141), and thrombosis (146), which 
could possibly counter-balance some of the detrimental effects of saturated fatty 
acids.  
Phytochemicals other than the anti-oxidants may also influence serum cholesterol 
levels. For example, phytosterols, which are plant derived steroid compounds 
with similar chemical structure as cholesterol, could reduce absorption of 
cholesterol in human intestine through competition for micelle formation (147). 
Supplementation with phytosterol has been an effective lipid lowering therapy 
(148). In contrast, dietary squalene, the biochemical precursor of cholesterol, may 
increase total and LDL-cholesterol in humans (149, 150). 
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1.5.3 Public health relevance in Singapore 
In view of the conflicts about the detrimental and beneficial components of palm 
oil as discussed above, it is important to assess the effect of palm oil consumption 
as a whole. Mixed findings were reported from human feeding trials of palm oil 
on blood lipids. A systematic review is thus necessary to summarize the evidence 
and to identify possible reasons for the heterogeneity of observations. 
As a tropical country, Singapore is a close neighbor to two of the largest palm oil 
exporter countries, Malaysia and Indonesia. Palm oil is the most commonly used 
cooking oil in Singapore for both home cooked and restaurants prepared foods 
(109). Hence, the health effect of palm oil is of special interest in the local context. 
The Singapore Health Promotion Board has launched the Healthier Ingredient 
Scheme earlier this year to subsidize for healthier cooking ingredients (151). 
Cooking oil, being the major source of fat in Singapore diet, is listed as the first 
ingredient under this scheme. Healthier cooking oils with less than 35% saturated 
fat content are subsidized to replace ‘unhealthy oils’, including highly saturated 
oils such as palm oil. Such policy decisions will greatly benefit from firm 
scientific support of a systematically conducted review of available evidence on 
the health impact of palm oil. 
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CHAPTER 2. RESEARCH AIMS 
The general research aim for this thesis is to explore the role of dietary fatty acids 
and their plasma biomarkers in the development of coronary heart disease, and to 
examine the potential mediating factors of this relationship including oxylipins, 
lipids, blood pressure, and inflammation (Figure 2-1). Specifically, the research 
aim will be investigated through the following three studies:  
1) Study I involves a systematic review of clinical trials with a meta-analysis to 
examine the influence of palm oil consumption on blood lipids (Chapter 3); 
2) Study II established a nested case-control study to assess the prospective 
association between plasma fatty acids, oxylipins, and risk of myocardial 
infarction, and to explore potential mediation through blood lipids, blood pressure, 
and inflammation (Chapter 4); 
3) Study III furthers an in-depth analysis of Study II to examine dietary and 
plasma biomarkers of plant- versus marine- based omega-3 fatty acids and risk of 
myocardial infarction through mediation by blood lipids and blood pressure 
(Chapter 5). 
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Figure 2-1. Diagram of major research hypotheses 
Study I (palm oil meta-analysis) will examine the pathway of dietary fatty acids → 
plasma lipids; Study II (plasma fatty acids, oxylipins and AMI risk) will explore the 
mechanism of plasma fatty acids → oxylipins → plasma lipids/blood 
pressure/inflammation → risk of coronary heart disease; Study III (n-3 fatty acids and 
AMI risk) will study the relationship of dietary fatty acids → plasma fatty acids → 
plasma lipids/blood pressure/inflammation → risk of coronary heart disease.
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CHAPTER 3. STUDY I: PALM OIL CONSUMPTION 
AND BLOOD LIPIDS 
This chapter was based on the following manuscript published in the Journal of 
nutrition: 
Sun Y, Neelakantan N, Wu Y, Lote-Oke R, Pan A, van Dam RM*. Palm oil 
consumption increases LDL cholesterol compared with vegetable oils low in 
saturated fat in a meta-analysis of clinical trials. J Nutr 2015;145(7):1549-58. 
 
3.1 INTRODUCTION 
Coronary heart disease (CHD) is the leading cause of mortality worldwide (152). 
The incidence of CHD is also increasing rapidly in many Asian countries in 
parallel with changes in diet (153, 154). Saturated fat increases total and LDL-
cholesterol concentrations (58) and risk of CHD events (96) when replacing 
polyunsaturated fat. However, a recent meta-analysis has found little impact of 
saturated fat on CHD mortality (30). When examining the different nutrient 
replacement scenarios separately, another meta-analysis suggested that 
replacement of saturated fat with sugars and refined carbohydrates, unlike 
replacement with polyunsaturated fat, is not likely to be beneficial (28). It is 
therefore important to gather more definitive data on the effects of saturated fat-
rich oils on cardiovascular disease markers such as LDL-cholesterol when 
replaced by other oils rich in unsaturated fats.  
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Palm oil is a type of edible oil obtained from the mesocarp of the fruits of the 
tropical plant, Elaeis guineensis. Palm oil represents 30% of the world vegetable 
oil production, and its consumption has increased rapidly in the past several 
decades particularly in emerging economies such as India and China (155). 
Compared to most other vegetable oils such as olive and sunflower oils, palm oil 
contains a high amount of saturated fat (40-50% of total fat) with the majority 
being palmitic acid. Although palm oil and animal fat have similar saturated fat 
content, the positional distribution of fatty acids in triglycerides is different: 70% 
of the palmitic acid in palm oil is in the sn-1 and sn-3 positions of triglycerides; 
while the majority of palmitic acid in animal fat is in the sn-2 position (136). Fatty 
acids in the sn-2 position might have an enhanced absorption (132), and thus, 
some researchers have suggested that the palmitic acid in palm oil may be less 
hypercholesterolemic and atherogenic than that in animal fat (137). A more recent 
study found palmitic acid in the sn-2 position could decrease postprandial lipemia 
in human (156). The impact on postprandial triglyceride absorption of palmitic 
acid with altered triacylglycerol structures has yet to be fully established (157).  
Trans-fat increases LDL-cholesterol and decreases HDL-cholesterol (158, 159). 
Palm oil has been suggested as an alternative for partially hydrogenated fats in the 
food supply to reduce trans-fat intakes while maintaining the sensory 
characteristics of foods (104). 
Taxation of palm oil in countries with high consumption has been proposed as a 
policy to reduce deaths due to cardiovascular diseases (160). However, is has 
been argued that results from trials of the effect of palm oil on blood lipids have 
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been too inconsistent to provide a firm basis for conclusions on the health impact 
of palm oil (161). The variation in study results might be due to differences in 
study design and study quality, study population, level of intake, and methods of 
preparation of study foods. There has been one meta-analysis (161) comparing 
palm oil and alternative cooking oils, but the study has several limitations in its 
design and conduct: lack of homogeneous intervention definition in study 
selection, no quality assessment of the included trials, and inadequate subgroup 
analyses. To address some of the questions unresolved, we conducted a 
systematic review and meta-analysis of clinical trials to investigate the effects of 
palm oil consumption on blood lipid profile (total, LDL- and HDL-cholesterol, 
and triglycerides) as compared with vegetable oils low in saturated fat, trans-fat 
containing partially hydrogenated vegetable oils, or animal fat. 
 
3.2 METHODS 
The research protocol was registered with PROSPERO registry 
(CRD42012002601), and was followed closely during the study. 
Study identification and selection 
Two biomedical literature databases – PubMed and the Cochrane library were 
searched for published reports of clinical trials about the effect of palm oil feeding 
on blood lipids up until 30 May 2014. Some relevant reviews, editorials, and the 
references from the selected articles were also checked to identify potential 
eligible studies not captured by the databases. Combinations of keywords related 
to the intervention (palm oil), study design (trials), study subjects (humans), and 
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outcome measures (cholesterol, LDL, HDL, triglycerides) were used in the 
literature search (a detailed search strategy is provided in section 3.5 supplemental 
text).  
After removing the duplicated results from the database search, two investigators 
first independently screened the studies for eligibility based on titles and abstracts. 
The full text articles of the potentially eligible studies were then obtained and 
independently screened by two investigators. Disagreements were resolved by 
consensus or in consultation to a third investigator. The inter-rater agreement was 
good (weighted kappa statistic = 0.74). 
The inclusion criteria for study selection are: 1) the study is a clinical trial 
conducted in human subjects; 2) the intervention is feeding of palm oil or palm 
olein, provided either as cooking oil or as cooked food; 3) the comparison is 
feeding of any vegetable oil low in saturated fat, partially hydrogenated vegetable 
oil (trans-fat containing), or saturated animal fat; 4) The feeding period is at least 
2 weeks, the time required to ensure stabilized blood lipid concentrations (162, 
163); 5) the outcome includes blood lipid concentrations: total, LDL-cholesterol 
(directly measured or calculated), HDL-cholesterol, and triglycerides. We 
excluded literature reviews, cross-sectional studies, non-human studies, studies 
with inappropriate intervention (e.g. palm stearin, palm kernel oil, red palm oil, or 
combination of palm oil with other saturated oils), studies with no or 
inappropriate comparison oil (e.g. coconut oil which is a saturated fat-rich 
vegetable oil), studies with duration less than 2 weeks, and studies with irrelevant 
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outcomes. According to these criteria, a total of 30 articles were included in the 
qualitative and quantitative synthesis. 
Data extraction and quality assessment 
Details about general characteristics (authors, title, year of publication, country), 
study characteristics (design, setting, sample size, randomization, blinding, 
duration, funding source, and drop-out rate), participant characteristics (age, 
gender, health conditions), intervention characteristics (level of intake, 
preparation method of test oil), type of control oil, and type of outcomes were 
extracted by reviewers using a standardized data extraction form. 
The quality of the included studies was assessed using the Jadad scoring for 
clinical trials (164). The score has a scale of 0 to 5, with each point being awarded 
for random allocation, valid description of randomization method, double 
blinding, valid description of double blinding, and description of drop-outs and 
withdrawals. A higher score indicates a better quality. Other individual study 
quality aspects such as concealment of treatment allocation and effort to check 
compliance were considered. 
Data on means and standard deviations (SD) at the end of the intervention for 
each outcome of interest were extracted. If there were multiple comparison arms, 
all relevant arms were combined to create a single pair-wise comparison to avoid 
double counting and correlated comparisons (165). Values reported in mg/dL 
were converted to mmol/L. If SDs were not reported, they were calculated or 
estimated from standard errors (SEs), confidence intervals (CIs), p-values for 
difference in means, or pooled correlation coefficients between baseline and final 
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measurements from trials reporting sufficient information (details provided in 
section 3.5 supplemental text) (165).  
Statistical analysis 
For crossover trials, the net change in the outcome measures was calculated as the 
end value after palm oil intervention minus the end value after control 
intervention. For parallel trials, the net change was calculated as the change-from-
baseline in palm oil group minus the change-from-baseline in control oil group. 
The pooled effect estimate combining results from parallel and crossover trials 
was obtained by combined design meta-analysis (166). Weighted mean 
differences and 95% CIs were calculated using the DerSimonian and Laird 
random-effects model that takes into account between-study variation in results.  
Heterogeneity in results of the included studies was quantified by the I2 statistic. 
The I2 represents the percentage of variation across studies that is due to between-
study heterogeneity rather than chance (167). Potential sources of heterogeneity 
were investigated using pre-specified stratified analyses and meta-regression 
according to various study characteristics: study design, duration of follow-up, 
geographical location, funding sources, randomization, blinding, effort to check 
compliance, Jadad score, study precision, gender, cholesterol level at entry, level 
of intake of the test oils, and type of control oil. Meta-regression was also used to 
assess the significance of differences between strata.  
In order to reduce the heterogeneity of studies due to the differences in types of 
control oils used and the level of test oil intake, we calculated the expected change 
in blood lipids based on the fatty acid composition (total saturated, 
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monounsaturated, polyunsaturated, and trans-fatty acids) of palm oil and the 
comparison oils and the level of intake of the oils using the Katan calculator (168) 
which is based on meta-analyses of published data from feeding studies (158). 
The expected (calculated) values for change in blood lipids were then subtracted 
from the observed (reported) values. Subsequently, subgroup and meta-regression 
analyses were conducted on these observed minus expected values to examine 
potential sources of heterogeneity independent of level of intake and fatty acid 
composition of the control oil. 
Publication bias was investigated by visual inspection of a funnel plot (169), and 
by Begg’s adjusted correlation test (170) and Egger’s regression test (171). The 
robustness of the findings of the meta-analysis were examined in a sensitivity 
analysis, where the pooled effect estimates were computed omitting one study at a 
time to assess the influence of each individual study. All tests were two-sided, and 
p<0.05 was considered statistically significant. All analyses were conducted using 
Stata version 11 (StataCorp, College Station, Texas). 
 
3.3 RESULTS 
A total of 373 potentially relevant articles from the literature search were screened 
based on titles and abstracts, and 39 full-text articles were reviewed in detail. Of 
these, 30 articles (172-201) reporting 32 studies met the inclusion criteria for the 
meta-analysis. The study selection flow diagram is shown in Figure 3-1. 
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Figure 3-1. Flow diagram for selection of studies for meta-analysis 
 
Among these studies, 27 studies compared palm oil with vegetable oils low in 
saturated fat, 9 studies compared palm oil with partially hydrogenated oils, and 2 
studies compared palm oil with animal fat. The characteristics of the included 
studies are summarized in Table 3-1. 
Palm oil versus vegetable oils low in saturated fat 
For the palm oil versus vegetable oils low in saturated fat comparison, a total of 
807 participants started the trials, and 764 (94.7%) of these subjects completed the 
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trials. 24 trials had a crossover design, and 3 had a parallel design. The estimated 
level of intake of test oil varied across studies from 12% to 43% of total energy 
intake, and the duration of intervention ranged from 2 to 16 weeks. More than half 
of the studies were conducted in western countries. The majority of the studies 
(n=15) were funded partially or completely by industry rather than government. 
Twenty studies provided meals or foods cooked with the test oil for all meals on 
all days throughout the trial period; another 4 studies only provided cooked meals 
for some meals of the day or for some days of the week (usually on weekdays); 
the remaining 3 studies provided the test oil as cooking oil for the subjects to cook 
at home. Most of the studies (n=19) were randomized trials. According to the 
Jadad score, 15 of the trials had low quality (with a score of 0 or 1 out of 5), while 
12 trials had medium to high quality (with a score of 2 to 4). The relatively low 
quality scores reflect that most studies did not describe the method of generating 
randomization sequence and the method of double blinding. None of the studies 






















Table 3-1. Characteristics of the clinical trials comparing palm oil with (1) vegetable oils low in saturated fat, (2) trans-fat 
containing oils, and (3) animal fat in humans 1 
Author, publication year 








age Control oil 
En% 
from 
test oil Male 
Dura
-tion 
        
 
    y   % wk 
(1) Palm oil vs Vegetable oils low in saturated fat 
Cater et al, 2001 (173) US RC No 7 1 Gov 66 Oleic SFO 43 100 3 
Cater et al, 1997 (174) US RC No 9 1 Gov 66 Oleic SFO 43 100 3 
Choudhury et al, 1995 (175) Australia RC No 21 2 Ind 27.8 OO 17 47.6 4 
Choudhury et al, 1997 (176) Australia RC Yes 42 4 Ind 37.2 Oleic SFO NR 57.1 3 
Denke et al, 1992 (177) US RC No 14 1 Gov 63 Oleic SFO 40 100 3 
Ghafoorunissa et al, 1995 (178) India C No 12 0 Ind 35 PNO 17.5 100 8 
Ghafoorunissa et al, 1995 (178) India C No 24 0 Ind 40.5 PNO 20 50 16 
Ng et al, 1992 (184) Malaysia RC No 33 1 Ind 28.7 OO 23 60.6 6 
Noakes et al, 1996 (185) Australia RC Yes 23 3 Ind 53 Oleic SFO 20 39.1 3 
Sánchez-Muniz et al, 2002 (186) Spain C No 14 0 Gov 62.9 Oleic SFO 28.5 0 4 
Sundram et al, 1997 (189) Malaysia RC Yes 27 2 Ind 29.4 CNO+SFO 21.2 66.7 4 
Tholstrup et al, 2011 (190) Denmark RC Yes 32 2 Ind 29.6 OO 17 100 3 
Truswell et al, 1992 (191) Australia RC Yes 21 3 Ind NR CNO NR 57.1 2 
Truswell et al, 1992 (191) Australia RC Yes 30 3 Ind NR CNO NR 43.3 3 
Utarwuthipong et al, 2009 (192) Thailand RC No 16 2 Gov 44-67 SBO&RBO 20 0 10 
Vega-López et al, 2006 (193) US RC Yes 15 2 Gov 63.9 SBO&CNO 20 33.3 5 
Voon et al, 2011 (194) Malaysia RC No 45 2 Ind 30.1 OO 20 20 5 
Zhang et al, 1997 (196) China C No 51 0 Ind 32-68 PNO 18-19.5 60.8 6 
Marzuki et al, 1991 (179) Malaysia C No 110 0 Gov 16-17 SBO NR 100 5 
Mattson et al, 1985 (180) US RC No 20 1 Gov 58.7 
Oleic&Linoleic 
SAO 
40 100 4 





















Bosch et al, 2002 (172) Venezuela P Yes 30 1 NR 19-45 SBO+SFO NR 75 12 
Ng et al, 1991 (183) Malaysia RP Yes 53 3 Ind 23.9 CO 22.5 73.5 5 
Scholtz et al, 2004 (187) ZAF RP No 38 2 Ind 48.3 Linoleic SFO 12 64.3 4 
Bonanome et al, 1988 (197) US RC No 11 1 NR 64 Oleic SAO 40 100 3 
Sundram et al, 1995 (200) Malaysia RC No 23 1 NR 22 CNO 20 100 4 
Cuesta et al, 1998 (198) Spain C No 14 1 Gov 63 Oleic SFO 28.4 0 4 
(2) Palm oil vs Trans-fat containing partially hydrogenated vegetable oils 
Noakes et al, 1996 (185) Australia RC Yes 23 3 Ind 53 trans blend 20 39.1 3 
Sundram et al, 2003 (188) Malaysia RC No 10 1 Ind NR HSBO 20.1 0 4 
Sundram et al, 1997 (189) Malaysia RC Yes 27 2 Ind 29.4 HSBO 21.2 66.7 4 
Vega-López et al, 2006 (193) US RC Yes 15 2 Gov 63.9 HSBO 20 33.3 5 
Mensink, 2008 (181) NLD RC Yes 44 4 Ind 41 HCNO 15 25 3 
Wood et al, 1993 (195) US C No 29 0 Ind 41 margarine 18-20 100 6 
Muller et al, 1998 (199) Norway C No 27 1 Ind 27 margarine 22.4 0 2.4 
Sundram et al, 2007 (201) Malaysia RC No 30 2 Ind 30 HSBO 21.7 34.4 4 
Mutalib et al, 1999 (182) UK RP No 43 1 NR NR HCNO&HSBO 26 100 8 
(3) Palm oil vs Animal fats 
Tholstrup et al, 2011 (190) Denmark RC Yes 32 2 Ind 29.6 lard 17 100 3 
Wood et al, 1993 (195) US C No 29 0 Ind 41 sweet butter 18-20 100 6 
1. For ‘Control oil’ column, ‘+’ indicates a mixture of oils in the same intervention arm; ‘&’ indicates two intervention arms using two different 
oils. Abbreviations: C: (non-randomized) crossover; CNO: canola oil; CO: corn oil; En%: percentage of total daily energy intake; Gov: 
government funding; HCNO: partially hydrogenated canola oil; HSBO: partially hydrogenated soybean oil; Ind: industry funding; NLD: 
Netherland; NR: not reported; OO: olive oil; P: (non-randomized) parallel; PNO: peanut oil; RBO: rice bran oil; RC: randomized crossover; RP: 
randomized parallel; SAO: safflower oil; SBO: soybean oil; SFO: sunflower oil; ZAF: South Africa. 
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The results from individual trials and the pooled effect estimates are shown in 
Figure 3-2 & 3-3, and summarized in Table 3-2. Overall, palm oil increased total 
cholesterol significantly as compared with the vegetable oils low in saturated fat 
by 0.35 mmol/L (95% CI: 0.23, 0.47 mmol/L; I2=86.0%), increased LDL-
cholesterol by 0.24 mmol/L (95% CI: 0.13, 0.35 mmol/L; I2=83.2%), and 
increased HDL-cholesterol by 0.02 mmol/L (95% CI: 0.01, 0.04 mmol/L; 
I2=49.8%). Palm oil did not change concentrations of triglycerides significantly as 
compared with the control oils. Because results of the meta-analysis were similar 
for total and LDL-cholesterol and LDL-cholesterol is a more specific outcome, 
we focused on LDL-cholesterol for subsequent analyses.  
Table 3-2. Pooled estimates for effects on blood lipids for the comparisons 
between palm oil and (1) vegetable oil low in saturated fat, (2) Trans-fat 
containing oils, and (3) animal fat in humans 1 
Outcome type Effect size 95% CI I2 n of studies 
 mmol/L   
(1) Palm oil vs Vegetable oils low in saturated fat 
Total cholesterol 0.35 (0.23, 0.47) 86.0% 27 
LDL-cholesterol 0.24 (0.13, 0.35) 83.2% 26 
HDL-cholesterol 0.02 (0.01, 0.04) 49.8% 26 
Triglycerides -0.02 (-0.08, 0.05) 63.4% 25 
(2) Palm oil vs Trans-fat containing partially hydrogenated vegetable oils 
Total cholesterol 0.11 (-0.07, 0.29) 86.7% 9 
LDL-cholesterol 0.05 (-0.13, 0.23) 88.1% 9 
HDL-cholesterol 0.09 (0.06, 0.11) 47.8% 9 
Triglycerides 0.00 (-0.06, 0.06) 64.3% 9 
(3) Palm oil vs Animal fats 
Total cholesterol 0.00 (-0.08, 0.08) 0.0% 2 
LDL-cholesterol -0.01 (-0.08, 0.07) 14.7% 2 
HDL-cholesterol 0.00 (-0.03, 0.04) 37.5% 2 
Triglycerides 0.02 (-0.18, 0.22) 71.7% 2 





















Figure 3-2. Effect of palm oil versus vegetable oils low in saturated fat on LDL-cholesterol in humans 
The squares and the horizontal lines represent individual points of estimate and their 95% CIs. The open diamond represents the pooled estimate 
and its 95% CI. For ‘Control oil’ column, ‘+’ indicates a mixture of oils in the same intervention arm; ‘&’ indicates two intervention arms using 
two different oils combined as one comparison arm. Abbreviations: En%: percentage of total daily energy intake; ES: effect estimate (in mmol/L); 





















Figure 3-3. Effect of palm oil versus vegetable oils low in saturated fat on HDL-cholesterol in humans 
The squares and the horizontal lines represent individual points of estimate and their 95% CIs. The open diamond represents the pooled estimate 
and its 95% CI. For ‘Control oil’ column, ‘+’ indicates a mixture of oils in the same intervention arm; ‘&’ indicates two intervention arms using 
two different oils combined as one comparison arm. Abbreviations: En%: percentage of total daily energy intake; ES: effect estimate (in mmol/L); 
NR: not reported. 
Chapter 3. Study I: Palm oil meta-analysis 
- 42 - 
 
Stratified analyses suggested that there were significant differences in the effects 
of palm oil on LDL-cholesterol according to various study characteristics 
including amount of test oil and the type of control oil (Table 3-3). In addition, 
government funding, conduct in a western country, use of randomization, a higher 
study quality score, and efforts to check compliance were associated with larger 
effects of palm oil on LDL-cholesterol. We used two approaches to control for 
amount of oil tested and the type of control oil used. First, we conducted meta-
regression for significant sources of heterogeneity adjusting for amount of test oil 
(% En) or type of control oil. Amount of test oil largely explained the observed 
difference between government vs. industry funded studies (adjusted p=0.23), but 
not the differences by country (adjusted p<0.001). Type of control oil explained 
the observed difference between studies conducted in western vs. Asian countries 
(adjusted p=0.39), but not the differences in effect by funding source (p=0.008). 
The second approach we took to control for amount of oil and type of control oil 
was to conduct a meta-analysis of the observed minus expected values. Expected 
values were based on the Katan formula which considers the amount and 
composition of the compared oils. Consistent with the meta-regression approach, 
funding (government vs. industry) and country (western vs. Asian) were not 
significantly associated with the effect size independent of amount and type of 
control oil (Table 3-3). In contrast, effects on LDL-cholesterol remained stronger 
for randomized studies (p=0.01) and studies with a higher Jadad quality score 
(p=0.05). In addition, a sex difference emerged in this analysis with stronger 
effects in studies of females than in studies of males (p=0.05). The difference in 
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observed minus expected values by randomization (p=0.01) and gender (p=0.01) 
stayed significant in bivariate meta-regression. 



















Table 3-3. Pooled estimates of effects on LDL-cholesterol and observed minus Katan expected effects within various subgroups 
for the comparison between palm oil and vegetable oils low in saturated fat in humans 1 





(95% CI) I2 Pdiff PEM 
Net 
change 
(95% CI) I2 Pdiff PEM 
  mmol/L 
   
mmol/L 
    
Overall 0.24 (0.13, 0.35) 83.20% 
  
-0.25 (-0.35, -0.16) 76.80% 
  
26 
Type of control oil 
           
 
Oleic safflower oil 0.57 (0.30, 0.83) 0.00% 0.91 
0.02 




Oleic sunflower oil 0.54 (0.38, 0.70) 42.40% Ref -0.13 (-0.27, 0.02) 29.60% Ref 6 
 
Linoleic sunflower oil 0.33 (-0.01, 0.68) 63.50% 0.26 -0.37 (-0.77, 0.03) 73.40% 0.57 2 
 
Soybean oil 0.33 (-0.18, 0.83) 78.10% 0.06 -0.16 (-0.79, 0.47) 86.00% 0.66 3 
 
Canola oil 0.2 (0.06, 0.33) 4.90% 0.05 -0.29 (-0.49, -0.08) 53.20% 0.44 4 
 
Olive oil 0.11 (-0.02, 0.25) 50.70% 0.004 -0.16 (-0.26, -0.06) 23.40% 0.75 4 
 
Peanut oil -0.15 (-0.38, 0.08) 73.60% <0.001 -0.31 (-0.50, -0.12) 61.10% 0.77 3 
 
Others (rice bran, corn, safflower, 
mixtures) 
0.21 (-0.07, 0.48) 67.80% 0.02 -0.17 (-0.52, 0.17) 80.20% 0.82 5 
Funding source 
           
 
Government funding 0.56 (0.25, 0.88) 84.60% Ref 
0.004 




Industry funding 0.12 (0. 00, 0.25) 80.70% 0.005 -0.23 (-0.32, -0.15) 58.60% 0.78 15 
 
Not reported 0.18 (-0.11, 0.46) 86.10% 0.06 -0.43 (-0.63, -0.23) 72.10% 0.15 3 
Geographical location 
           
 
Western (USA, AUS, ESP, DNK) 0.39 (0.27, 0.51) 62.10% Ref 
0.06 




Asian (MYS, IND, CHN, THA) 0.01 (-0.12, 0.14) 72.10% 0.001 -0.29 (-0.44, -0.15) 76.30% 0.25 10 
 
Others (VEN, ZAF) 0.22 (-0.34, 0.78) 90.20% 0.2 -0.39 (-0.81, 0.02) 82.10% 0.13 2 



















Level of intake (%En) of test oil2 
           
 
>= 30% 0.63 (0.47, 0.78) 0.00% Ref 
0.01 




20% - < 30% 0.24 (0.08, 0.40) 70.40% 0.02 -0.13 (-0.26, 0.01) 57.60% 0.08 10 
 
< 20% 0.06 (-0.20, 0.32) 90.60% 0.001 -0.32 (-0.49, -0.15) 75.60% 0.56 6 
Study design 
           
 
Crossover 0.24 (0.12, 0.35) 83.30% Ref 
0.87 




Parallel 0.31 (-0.19, 0.81) 84.50% 0.87 -0.23 (-0.69, 0.24) 70.20% 0.53 3 
Jadad score 
           
 
3 – 4 0.31 (0.18, 0.43) 0.00% Ref 
0.02 




1 – 2 0.32 (0.18, 0.46) 81.40% 0.95 -0.21 (-0.33, -0.08) 76.60% 0.66 16 
 
0 -0.06 (-0.24, 0.11) 76.40% 0.04 -0.43 (-0.61, -0.26) 77.50% 0.05 5 
Double blinding 
           
 
Yes 0.21 (0.07, 0.34) 73.00% Ref 
0.88 




No 0.26 (0.09, 0.42) 86.40% 0.88 -0.28 (-0.39, -0.17) 67.10% 0.47 17 
Randomization 
           
 
Yes 0.31 (0.20, 0.42) 65.00% Ref 
0.02 




No 0.03 (-0.15, 0.2) 84.80% 0.02 -0.4 (-0.56, -0.24) 81.90% 0.01 7 
Effort to check compliance 
           
 
Direct observation 0.41 (0.17, 0.65) 81.20% Ref 
0.13 




Diet record/diary/24hr recall 0.16 (0.06, 0.27) 56.40% 0.11 -0.29 (-0.45, -0.12) 83.60% 0.38 9 
 
Plasma fatty acid profile only 0.37 (-0.04, 0.79) 76.50% 0.9 -0.17 (-0.38, 0.04) 14.80% 0.85 4 
 
None 0.01 (-0.22, 0.23) 87.10% 0.04 -0.35 (-0.58, -0.12) 86.90% 0.24 4 
Subjects cholesterol level at entry 
           
 
Hypercholesterolemic 0.39 (0.04, 0.75) 91.60% Ref 
0.29 




Normocholesterolemic 0.31 (0.08, 0.54) 78.50% 0.85 -0.2 (-0.40, -0.01) 68.40% 0.83 5 
 
Mixed/Not reported 0.14 (0.04, 0.25) 66.50% 0.19 -0.3 (-0.42, -0.18) 74.80% 0.55 15 




















           
 
Male 0.21 (0.05, 0.38) 86.50% Ref 
0.72 




Female 0.32 (0.05, 0.59) 72.50% 0.5 -0.13 (-0.28, 0.01) 9.50% 0.05 6 
 Mixed 0.19 (-0.02, 0.40) 85.00% 0.84 -0.19 (-0.31, -0.06) 58.30% 0.07 10 
Method of oil provision 
           
 
Cooked meals/foods on all days 0.32 (0.17, 0.47) 86.00% Ref 
0.14 




Cooked meals for some meals/on 
some days 
0 (-0.09, 0.09) 12.50% 0.06 -0.31 (-0.56, -0.06) 88.40% 0.58 4 
  Cooking oil only 0.12 (-0.21, 0.44) 54.20% 0.37 -0.14 (-0.34, 0.06) 13.80% 0.43 3 
1. Values are the pooled effect sizes and the 95% CIs. Net change is expressed as the change during intervention with palm oil minus the change 
during the control oil. ‘Observed values’ are the reported net changes between intervention and control groups, while ‘Observed - expected values’ 
are calculated as the reported net changes minus the expected net changes predicted by the Katan calculator. Pdiff: p-value from meta-regression 
comparing with the reference stratum; PEM: p-value for effect modification tested by one-way ANOVA F-test; Ref: reference stratum. 
2. Five of the studies did not report level of intake of test oils, and were thus excluded in this subgroup analysis. 
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Overall, the effect of palm oil on LDL-cholesterol was 0.25 mmol/L lower than 
expected (95% CI: 0.16, 0.35 mmol/L) based on the Katan calculator, with a 
smaller difference for randomized trials (0.19 mmol/L; 95% CI: 0.12, 0.26 
mmol/L). After taking into account amount and composition of oils in this 
analysis, the remaining heterogeneity among randomized trials was modest 
(I2=27.5%, p for heterogeneity=0.13). 
For effects on HDL-cholesterol, only study design (P<0.001) and method of oil 
provision (P=0.03) were significantly associated with the strength of effects. 
Crossover trials (n=24) and studies that provided meals for all days (n=19) 
showed that palm oil significantly increased HDL-cholesterol, whereas the 
smaller number of studies that had a parallel design (n=2) or did not provide 
meals on all days (n=4) did not show an increase in HDL-cholesterol. Based on 
the Katan calculator, observed effects on HDL-cholesterol were not significantly 
different from expected effects (difference -0.01 mmol/L; 95% CI: -0.03, 0.02 
mmol/L).  
Sensitivity analysis in which we removed studies one at a time did not 
substantially change the differences in effect on LDL-cholesterol with effect 
estimates ranging from 0.21 mmol/L (95% CI: 0.11, 0.32 mmol/L) to 0.25 
mmol/L (95% CI: 0.15, 0.35 mmol/L). Similar sensitivity analysis also did not 
result in a substantial change in the pooled estimate for other lipid outcomes.  
Egger’s test (p=0.003), Begg’s test (p=0.03), and the funnel plot indicated that the 
comparisons between the effect of palm oil and vegetable oils low in saturated fat 
on LDL-cholesterol may be affected by publication bias (Figure 3-4). As 
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compared with larger studies (higher two tertiles of inverse SE), smaller studies 
(lowest tertile of inverse SE) were more likely to be randomized (83% vs. 50%, P 
for difference=0.08) and to provide a larger amount of test vegetable oil (>20 
percent of energy: 60% vs. 0%, P for difference=0.01). Egger’s test (p=0.05) and 
Begg’s test (p=0.12) gave weaker suggestion of publication bias when we 
excluded the 7 non-randomized studies. After also taking the amount of oil into 
consideration by using the observed minus expected values, Egger’s test (p=0.72) 
and Begg’s test (p=0.16) no longer suggest publication bias among the 
randomized trials. For effects on HDL-cholesterol, the funnel plot (Figure 3-5), 
Egger’s test (p=0.24), and Begg’s test (p=0.08) did not suggest publication bias. 
 
Figure 3-4. Funnel plot: comparison between palm oil and vegetable oils low 
in saturated fat on LDL-cholesterol 
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Figure 3-5. Funnel plot: comparison between palm oil and vegetable oils low 
in saturated fat on HDL-cholesterol 
 
Palm oil versus partially hydrogenated (trans-fat containing) oils 
The effect of palm oil versus partially hydrogenated vegetable oils was evaluated 
in 9 trials. In total, 260 subjects started the trials, and 248 (95.4%) completed the 
trials. The percentage of trans-fat in the partially hydrogenated oils varied from 
4.5% to 29.2%, and the estimated level of intake of trans-fat ranged from 0.7% to 
7.0% of total energy intake.  
Palm oil significantly increased HDL-cholesterol by 0.09 mmol/L (95% CI: 0.06, 
0.11 mmol/L; p<0.001) as compared with partially hydrogenated oils (Figure 3-
6). Consistent with the moderate heterogeneity in study results (I2=47.8%, 
p=0.05), this effect did not significantly differ between any of the examined strata. 
Overall, palm oil did not significantly change total cholesterol, LDL-cholesterol 
(Figure 3-7), or triglycerides when compared to partially hydrogenated oils 
(Table 3-2). 
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Figure 3-6. Effect of palm oil versus partially hydrogenated vegetable oils on 
HDL-cholesterol in humans 
The squares and the horizontal lines represent individual points of estimate and their 95% 
CIs. The open diamond represents the pooled estimate and its 95% CI. Abbreviations: 
En%: percentage of total daily energy intake; ES: effect estimate (in mmol/L). 
Given the large heterogeneity in study results (I2=88.1%), we conducted stratified 
analyses for effects on LDL-cholesterol. Palm oil increased LDL-cholesterol in 
studies in western countries (n=6), but decreased LDL-cholesterol in studies in 
Asia (n=3) as compared with partially hydrogenated oils (p for difference=0.008) 
(Table 3-4). The western studies provided all the test oil in cooked food, whereas 
the Asian studies also provided part of the test oil as cooking oil to subjects. In 
addition, the energy intake from trans-fat in the control oils was associated with 
the observed effect size (P=0.03), and was generally higher in the Asian studies 
than in the western studies (Table 3-1). Thus, the difference in effect according to 
country could not be separated from the effect of method of oil provision or the 
amount of trans-fat provided by the control oil.  
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Figure 3-7. Effect of palm oil versus partially hydrogenated vegetable oils on 
LDL-cholesterol in humans 
The squares and the horizontal lines represent individual points of estimate and their 95% 
CIs. The open diamond represents the pooled estimate and its 95% CI. Abbreviations: 




















Table 3-4. Pooled estimates of effects on LDL-cholesterol and observed minus Katan expected effects within various subgroups 
for the comparison between palm oil and partially hydrogenated vegetable oils 1 




(95% CI) I2 Pdiff PEM 
Net 
change 
(95% CI) I2 Pdiff PEM 
N of 
studies 
  mmol/L 
   
mmol/L 
   
  
Overall 0.05 (-0.13, 0.23) 88.10% 
  
-0.06 (-0.23, 0.12) 87.70% 
  
9 
Type of control oil 
           
 
hydrogenated soybean oil -0.1 (-0.37, 0.17) 80.40% Ref 
0.18 




hydrogenated rapeseed oil 0.35 (0.24, 0.47) 0.00% 0.08 0.25 (-0.22, 0.72) 75.40% 0.3 2 
 
margarine/trans blend oil 0.12 (-0.05, 0.30) 73.30% 0.31 -0.03 (-0.40, 0.34) 94.10% 0.43 3 
Funding source 
           
 
Government 0.08 (-0.11, 0.27) - Ref 
0.36 




Industry -0.01 (-0.22, 0.20) 90.40% 0.79 -0.12 (-0.32, 0.07) 88.60% 0.8 7 
 
NR 0.52 (0.14, 0.90) - 0.39 0.58 (0.21, 0.96) - 0.16 1 
Geographical location 
           
 
Western (USA, AUS, NLD, GBR) 0.19 (0.06, 0.33) 75.80% Ref 
0.01 




Asian (MYS) -0.28 (-0.44, -0.12) 15.90% 0.01 -0.29 (-0.40, -0.17) 0.00% 0.09 3 
Level of intake (%En) of trans-fat 
           
 
>= 5% -0.26 (-0.64, 0.12) 73.10% Ref 
0.04 




2.5% - < 5% 0.05 (-0.17, 0.27) 88.80% 0.19 -0.14 (-0.37, 0.10) 90.20% 0.16 4 
 
< 2.5% 0.36 (0.25, 0.47) 0.00% 0.03 0.29 (-0.22, 0.80) 85.20% 0.88 2 
Study design 
           
 
Crossover 0.01 (-0.18, 0.19) 88.80% Ref 
0.19 




Parallel 0.52 (0.14, 0.90) - 0.19 0.58 (0.21, 0.96) - 0.06 1 
Jadad score 
           
 
3 – 4 0.33 (0.23, 0.42) 0.00% Ref 
0.43 

























0 0.05 (-0.08, 0.18) - 0.46 -0.37 (-0.50, -0.24) - 0.24 1 
Double blinding 
           
 
Yes 0.17 (-0.04, 0.38) 78.30% Ref 
0.55 




No -0.02 (-0.23, 0.18) 82.10% 0.55 -0.08 (-0.34, 0.18) 89.40% 0.88 5 
Randomization 
           
 
Yes 0.04 (-0.21, 0.29) 90.90% Ref 
0.98 




No 0.04 (-0.06, 0.14) 0.00% 0.98 -0.12 (-0.61, 0.37) 94.90% 0.74 2 
Effort to check compliance 
           
 
Direct observation 0.03 (-0.34, 0.39) 87.80% Ref 
0.60 




Diet record/diary/24hr recall -0.04 (-0.30, 0.22) 90.50% 0.84 -0.19 (-0.44, 0.06) 89.70% 0.45 4 
 
Plasma fatty acid profile only 0.08 (-0.11, 0.27) - 0.88 -0.05 (-0.24, 0.14) - 0.91 1 
 
None 0.52 (0.14, 0.90) - 0.31 0.58 (0.21, 0.96) - 0.16 1 
Subjects cholesterol level at entry 
           
 
Hypercholesterolemic 0.2 (-0.02, 0.41) 68.10% Ref 
0.69 




Normocholesterolemic -0.07 (-0.45, 0.31) 82.40% 0.45 -0.16 (-0.60, 0.28) 87.00% 0.52 4 
 
Mixed/Not reported 0.05 (-0.32, 0.41) 95.20% 0.67 -0.03 (-0.28, 0.21) 89.40% 0.8 3 
Subjects gender 
           
 
Male 0.25 (-0.21, 0.70) 81.20% Ref 
0.50 




Female -0.15 (-0.53, 0.23) 76.80% 0.28 -0.06 (-0.48, 0.36) 80.90% 0.76 2 
 
Mixed 0.04 (-0.24, 0.32) 92.40% 0.49 -0.07 (-0.26, 0.13) 84.10% 0.66 5 
Method of oil provision 
           
 
Cooked meals/foods on all days 0.19 (0.06, 0.33) 75.80% Ref 
0.01 




Cooked meals for some meals/on 
some days 
-0.28 (-0.44, -0.12) 15.90% 0.01 -0.29 (-0.40, -0.17) 0.00% 0.09 3 
1. Values are the pooled effect sizes (95% CIs). Net change is the change during intervention with palm oil minus the change during the control oil. 
‘Observed values’ are the reported net changes between intervention and control groups, while ‘Observed - expected values’ are calculated as the 
reported net changes minus the expected net changes predicted by the Katan calculator. Pdiff: p value from meta-regression comparing with the 
reference stratum; PEM: p-value for effect modification tested by one-way ANOVA F-test; Ref: reference stratum. 
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Sensitivity analysis did not suggest that any one study unduly influenced the 
results for all outcomes. Visual inspection of the funnel plot (Figure 3-8), Egger’s 
test (p=0.55), and Begg’s test (p=0.60) did not suggest publication bias when 
LDL-cholesterol was considered as the outcome. However, the effect estimate for 
HDL-cholesterol might be subject to publication bias based on Egger’s test 
(p=0.06) and Begg’s test (p=0.18), and the funnel plot (Figure 3-9). 
 
Figure 3-8. Funnel plot: comparison between palm oil and partially 
hydrogenated vegetable oils on LDL-cholesterol 
 
Figure 3-9. Funnel plot: comparison between palm oil and partially 
hydrogenated vegetable oils on HDL-cholesterol 
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Palm oil versus animal fat 
Two crossover trials on palm oil versus animal fat comparison were both 
conducted in normocholesterolemic male subjects in western countries, were 
funded by industry, and supplied cooked foods to replace part the subjects’ usual 
diet. A randomized double blinded trial compared palm oil with lard (190), and 
the other trial which were not randomized or blinded compared palm oil with 
sweet butter (195). As shown in Table 3-2, the pooled results from the two studies 
did not show a significant difference between the two dietary groups for LDL-
cholesterol (-0.01 mmol/L, 95% CI: -0.08, 0.07 mmol/L; I2=14.7%) or any of the 
other blood lipids with limited heterogeneity in study results. 
 
3.4 DISCUSSION 
In this meta-analysis of clinical trials we found that palm oil significantly 
increased total, LDL- and HDL-cholesterol concentrations as compared with 
vegetable oils low in saturated fat. Palm oil was also found to significantly 
increase HDL-cholesterol as compared with trans-fat containing partially 
hydrogenated vegetable oils. There was no substantial difference between palm 
oil and animal fats for any of the blood lipids. 
The 0.24 mmol/L increase in LDL-cholesterol by palm oil may translate to a 6% 
higher risk of CHD mortality and total CHD events (202). Palm oil may result in a 
less desirable lipid profile than mostly unsaturated vegetable oils with regard to 
CHD risk, which is as expected based on the high saturated fatty acid content of 
palm oil (168). The observed effect of palm oil as compared with low saturated 
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fat vegetable oils on LDL-cholesterol in randomized trials was substantial, but 38% 
lower than expected based on the Katan calculator which is based on a meta-
analysis of large number of trials of fatty acid intakes and blood lipids. The reason 
for this difference is not clear and may be related to differences in characteristics 
of the study population, study design, or compliance to interventions.  
An important contributor to heterogeneity in study results in our meta-analysis 
appeared the quality of the included studies: palm oil substantially increased 
LDL-cholesterol in studies with randomization and a higher Jadad score, but not 
in the low quality studies. In addition, industry-funded studies and studies 
conducted in Asia tended to show weaker effects of palm oil on LDL-cholesterol 
than government-funded studies and those conducted in western countries. 
Industry funding of nutrition-related scientific articles may bias conclusions in 
favor of sponsors’ products (203). In our meta-analysis, industry funded studies 
appeared to report weaker effects on LDL-cholesterol because the amount of test 
oil provided was smaller than for government funded studies. In contrast, Asian 
studies appeared to report weaker effects because of the type of vegetable oil used 
in the control group.  
Replacing partially hydrogenated oils with palm oil increased HDL-cholesterol, 
but had inconsistent effects on LDL-cholesterol in our meta-analysis. Palm oil 
increased LDL-cholesterol in the studies conducted in western countries that also 
had comparison oils lower in trans-fat and provided all test oils as prepared dishes. 
In contrast, palm oil decreased LDL-cholesterol as compared with partially 
hydrogenated oils in the Asian studies that had comparison oils higher in trans-fat 
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and provided part of the test oil as cooking oils. Given the limited number of trials, 
we could not separate the effect of trans-fat level, completeness of test oil 
consumption, and other factors related to geographical location. Mozaffarian et al. 
(159) observed that replacing saturated fat with trans-fat significantly decreased 
HDL-cholesterol and non-significantly increased LDL-cholesterol, which is 
consistent with our pooled estimates. The adverse effect of trans-fatty acids on 
blood lipids may be explained by its effects on hepatocytes to alter cholesterol 
secretion, lipoprotein composition, and apolipoprotein catabolism (204-206). 
Based on the meta-analysis of the two trials of palm oil versus animal fat, the 
different positional distribution of palmitic acid in triglycerides between palm oil 
and animal fat did not seem to affect their effects on blood lipids. Zock et al. (138) 
compared the effects of natural palm oil (18% of palmitic acid at the sn-2 position) 
with enzymatically modified palm oil (65% of palmitic acid at the sn-2 position), 
and they found that the differences in effects on blood lipids were minimal and 
non-significant. This supports that palmitic acid in sn-2 position does not result in 
a worse lipid profile than that in sn-1 and sn-3 position. In addition, Forsythe et al. 
(139) found that lard (39% saturated fat) consumption resulted in a modest but 
significant reduction in total cholesterol (0.2 mmol/L) and total-to-HDL ratio (0.5) 
as compared with palm stearin (50% saturated fat) in a crossover trial. These 
findings also suggested that the degree of saturation has a greater effect on blood 
lipid concentrations than the positional distribution of fatty acids.  
Fattore et al. (161) reported that consumption of palm oil instead of MUFA/PUFA 
dominating oils leads to a (borderline) significant increase in both LDL-
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cholesterol and HDL-cholesterol in their meta-analysis. They concluded that 
results were too heterogeneous to draw firm conclusions about the health effects 
of palm oil. However, this meta-analysis included trials that evaluated diverse test 
oils including palm oil, red palm oil, or other oils that were rich in palmitic acid 
and examined few potential sources of heterogeneity in study results. In contrast, 
our meta-analysis only included trials of the most typical type of palm oil / palm 
olein with 40-50% palmitic acid and 35-45% oleic acid. We also thoroughly 
assessed potential sources of heterogeneity including the quality of the included 
studies and included the novel approach of comparing observed effect sizes with 
expected effects based on prior knowledge.  
This meta-analysis was subject to several limitations. Firstly, several of the 
clinical trials included in this analysis had poor quality in their design, execution 
and data presentation, which may have resulted in biases. Our stratified analyses 
suggested that studies with better quality tended to report stronger LDL-
cholesterol-increasing effect by palm oil. Secondly, statistical tests suggested that 
publication bias might have affected the results for palm oil versus vegetable oils 
low in saturated fat. We cannot exclude the possibility that publication bias led to 
an over-estimate of the effect. However, we also observed that the smaller studies 
were more likely to be randomized and to have a higher level of oil intake as 
compared with larger studies. Such differences in study characteristics may have 
contributed to the ‘small study effect’ that tests for publication bias are based on. 
Lastly, this review focuses on the effect of dietary oils on intermediary 
biomarkers of disease such as serum cholesterol instead of disease outcomes. The 
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results on HDL-cholesterol need to be interpreted with caution in particular, as the 
causal relationship between HDL-cholesterol and CHD risk is controversial (207). 
To date, data on the effect of palm oil consumption on risk of cardiovascular 
diseases are sparse. In one case-control study conducted in Costa Rica (27) the 
association between palm oil consumption and non-fatal myocardial infarction 
was studied. In this study, the authors found that participants who usually use 
palm oil as the cooking oil have a higher risk of non-fatal acute myocardial 
infarction than those using soybean oil (odds ratio = 1.33, 95% CI: 1.08-1.63) and 
those using other cooking oils (mainly sunflower oil) (odds ratio = 1.23, 95% CI: 
0.99-1.52). The difference in myocardial infarction between palm oil users and 
high-trans soybean oil users were not significant (odds ratio = 1.14, 95% CI: 
0.84-1.56). These observations are consistent with the results for blood lipids 
from our meta-analysis. Still, more evidence from cohort studies and clinical trials 
on the effect of palm oil consumption on cardiovascular events is warranted. 
In conclusion, the saturated fat in palm oil seemed to have the same effects on 
LDL-cholesterol as that in animal fat. This is also reflected in the significant 
increase in LDL-cholesterol by palm oil when compared with vegetable oils low 
in saturated fat. Based on its unfavorable effects on LDL-cholesterol, saturated fat 
should, with little doubt, still be consumed with restraint and replaced by 
unsaturated fat where possible. Palm oil, with the lowest production cost among 
all vegetable oils (155), represents a significant source of saturated fat intake in 
many emerging economies, where the incidence of cardiovascular disease is 
increasing rapidly (208). Our results thus support reduction of the use of palm oil 
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by replacing it with vegetable oils that are low in saturated and trans-fat, as 
suggested by Basu et al (160) in their taxation model. For products that are 
consumed in minor amounts and currently use trans-fat for its sensory 
characteristics, palm oil may be a viable alternative given its more favorable 
effects on HDL-cholesterol. 
 
3.5 SUPPLEMENTAL TEXT 
Search terms in PubMed 
(palm oil* OR palm olein* OR palmolein* OR palmitic acid[mesh]) AND 
("randomized controlled trial" [pt] OR "controlled clinical trial"[pt] OR "clinical 
trial"[pt] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic 
[mesh: noexp] OR randomly [tiab] OR trial [tiab] OR crossover OR cross over 
OR cross-over) NOT (animals [mh] NOT humans [mh]) AND (cholesterol*[tiab] 
OR lipoprotein*[tiab] OR LDL*[tiab] OR HDL*[tiab] OR triglycer*[tiab] OR 
triacylglycer*[tiab] OR tg[tiab] OR TAG[tiab] OR lipid*[tiab] OR 
cholesterol[mesh] OR lipoproteins[mesh] OR LDL cholesterol[mesh] OR HDL 
cholesterol[mesh] OR triglyceride[mesh] OR lipids[mesh]) 
Search terms in Cochrane 
(palm oil OR palm olein OR palmolein OR palmitic acid) AND (cholesterol OR 
lipoprotein OR LDL OR HDL OR triglycer* OR triacylglycer* OR tg OR TAG 
OR lipid) in Trials 
Methods to impute for missing standard deviations for changes in blood 
lipids 
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If SDs were not reported, they were calculated from standard errors (SEs) and 
confidence intervals (CIs) if possible using standard formulae, or estimated from 
the reported p-values for difference in means (165). If only levels of significance 
were reported instead of exact p-values, a conservative approach was used to take 
the p-value as the upper limit (e.g. take p=0.05 if p<0.05 is reported). Estimates 
were obtained from figures if no numbers were reported. If none of the above 
information was available to estimate the SD of changes in blood lipids, we 
imputed the missing SDs by using the SDs of baseline and final measurements 
and an estimated correlation coefficient between baseline and final measurements. 
These correlation coefficients were estimated using the pooled correlation 
coefficient from each trial that reported sufficient information (165, 209) in a 
meta-analysis of transformed z scores (±SEs) (210). To investigate the effect of 
the imputed within-person correlation coefficients, sensitivity analysis was 
performed using a range of correlation coefficients (0, 0.25, 0.5, and 0.75) (211). 
This sensitivity analysis did not result in a substantial effect on the pooled results 
for any of the studied outcomes. 
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CHAPTER 4. STUDY II: PLASMA FATTY ACIDS, 
OXYLIPINS, AND ACUTE MYOCARDIAL 
INFARCTION 
This chapter was based on the following manuscript: 
Sun Y, Koh HWL, Choi H, Koh WP, Yuan JM, Newman JW, Su J, Fang J, Ong 
CN, and van Dam RM*. Plasma fatty acids, oxylipins, and risk of myocardial 




Dietary fatty acids (FAs) have been implicated in the etiology of coronary heart 
disease (CHD) through various biological mechanisms including atherosclerosis 
and thrombosis (58). Results from cohort studies suggest that long-chain n-3 
polyunsaturated FAs (PUFAs) are associated with a lower CHD risk and trans-fat 
are associated with a higher CHD risk (84, 212). Meta-analyses also showed 
lower cardiovascular risk associated with higher consumption of n-6 PUFAs (28, 
96), but concerns remain about their pro-inflammatory and pro-thrombotic 
potential through synthesis of oxidized metabolites (98, 99). In addition, n-6 and 
n-3 PUFAs compete for the same enzymes for elongation and desaturation, such 
that increased intake of n-6 PUFAs may lead to reduced endogenous production 
of the beneficial long-chain n-3 PUFAs (100). 
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Oxylipins are a group of oxidized metabolites of PUFAs through various 
enzymatic pathways. These include the more conventional subclass of 20-carbon 
oxylipins derived from arachidonic acid [AA, 20:4(n-6)] named eicosanoids, as 
well as other more recently found oxylipins that are metabolized via lipoxygenase 
(LOX) and cytochrome P450 (CYP450) pathways. Experimental studies have 
found that these oxylipins have hormone-like effects on inflammation, 
vasoconstriction and blood clotting (112), and thus they might be key mediators 
of dietary FAs on the cardiovascular system. For instance, thromboxane A2 
(TXA2) activates platelets and induces vasoconstriction (110); the arachidonate 
monohydroxide 12-hydroxyeicosatetraenoic acid (12-HETE) may upregulate 
platelet adhesivity, while the linoleate monohydroxide 13-hydroxy-
octadecadienoic acid (13-HODE) may suppress endothelial cell reactivity to 
platelets (114); epoxyeicosatrienoic acids (EETs) may be anti-inflammatory by 
reducing cytokine-induced leukocytes adhesion to vascular endothelium (113). 
Changes in dietary FA precursors were observed to change the balance of 
oxylipins with different biological effects (116, 117), thus potentially influencing 
the risk of CHD. However, epidemiological data on oxylipins and CHD risk are 
sparse. One study involving 30 human carotid atherosclerotic plaques found that 
the concentrations of HETEs were significantly elevated in symptomatic plaques 
as compared with asymptomatic plaques, but not that of EETs and 
ketoeicosatetraenoic acids (KETEs) (129). Two case-control studies observed 
elevated levels of plasma HETEs in coronary artery disease cases compared to 
controls (130, 131). Notwithstanding the abovementioned evidence, data from 
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larger prospective studies with comprehensive assessment of oxylipins are 
currently not available. To address some of these gaps of knowledge, we 
simultaneously quantified a wide range of plasma FAs and oxlipins, and evaluated 
their inter-correlations and associations with risk of acute myocardial infarction 
(AMI) in a case-control study nested within a cohort based in Singapore of 
Chinese origin. One of the difficulties of analyzing data on a large number of fatty 
acids and oxylipins is the high collinearity among these metabolites. To 
circumvent this problem, we have devised an automated approach to group the 
highly correlated metabolites into clusters and study their associations with 
cardiovascular risk.  
 
4.2 METHODS 
Singapore Chinese Health Study 
The Singapore Chinese Health Study (SCHS) is a population-based, prospective 
cohort study of 63,257 Chinese men and women (Hokkien or Cantonese dialect 
group) aged 45-74 years residing in public housing estates, where 86% 
Singaporeans resided at the time of recruitment. Recruitment and assessment of 
baseline diet, lifestyle, and medical history took place from 1993 to 1998. To date, 
follow-up surveys have been conducted twice (1999-2004; 2006-2010) to update 
information on use of tobacco and alcohol, medical history, and menopausal 
status. Blood specimens were also collected from 28,439 subjects during 1994-
2005. The cohort has been followed up for morbidity and mortality through 
record linkage with Singapore Registry of Births and Deaths, Hospital Discharge 
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Database, and Singapore Cancer Registry. All data on lifestyle and medical 
history were assessed using interviewer-administered standardized questionnaires 
(213). Information on education level, body mass index (BMI), physical activity, 
smoking and alcohol intake, and history of diabetes and hypertension were 
collected as previously described (214-216). This study was approved by the 
Institutional Review Board at the National University of Singapore, and all 
participants gave informed consent. 
Nested case-control study 
We have established a nested case-control study involving 744 incident AMI 
cases and 744 matched controls. These cases and controls were selected from the 
SCHS participants who provided blood and did not have a history of CHD or 
stroke at the time of blood collection based on self-reported diagnosis and data 
from the Hospital Discharge Database [International Classification of Diseases 
(ICD)-9 codes: 410-414, 427, 428, 430-434, 438]. 
Cases include incident nonfatal or fatal AMI occurring after blood specimen 
collection up until 31 December 2010. We identified and verified cases of AMI 
through linkage with three databases: 1) The national Mediclaim System Hospital 
Discharge Database (HDD), which has been in use in Singapore since 1990 and 
records up to 3 diagnoses per patient for inpatient discharges from public and 
private hospitals based on ICD-9 (217). We selected all participants who were 
identified as AMI cases (ICD-9: 410) in this database until 31 December 2010. 
The medical records of these participants were then reviewed by a cardiologist 
using the criteria of the Multi-Ethnic Study of Atherosclerosis (MESA) (218) and 
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only confirmed cases of AMI were included in our study. 2) The Singapore 
Myocardial Infarction Registry (SMIR), a centralized population-based registry 
that uses similar procedures as we used for HDD to confirm AMI based on a 
review of medical records (216). We only had access to cases up to 31 December 
2005 from SMIR, but these cases largely overlapped with the cases identified 
through the other databases. 3) The Singapore Registry of Births and Deaths. This 
registry codes causes of death according to ICD-9, and participants with codes 
410-414 (ischemic heart disease) stated as the primary cause of death were 
selected, which are assumed to be death from myocardial infarction in practice. A 
total of 744 unique AMI cases were identified and included in this study. 
Controls were selected using risk-set sampling (219): controls were participants 
who were alive and free of CHD at the time of the diagnosis or death of the 
respective indexed cases and matched (in 1-to-1 ratio) for sex, father’s dialect 
group, date of birth (± 2 years), date of recruitment (± 1 year) and date of blood 
collection (± 6 months). 
The study timeline and participant selection flow is demonstrated in Figure 4-1. 
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Figure 4-1. Flow chart of participants in the SCHS-AMI study. 
Abbreviations: AMI: acute myocardial infarction; CHD: coronary heart disease; FFQ: 
food frequency questionnaire; SCHS: Singapore Chinese Health Study. 
Assessment of cardiovascular risk factors 
Blood samples were collected during home visits during 1994-2005 and stored at 
-80°C. Systolic and diastolic blood pressure was measured by Omron blood 
pressure monitors three times using a standard protocol and the average of the 
three measurements was used for statistical analysis. Conventional biochemical 
risk factors of CHD were measured by National University Hospital referral 
laboratories. Total, HDL and LDL (directly measured) cholesterol and 
triglycerides were measured using enzymatic, calorimetric methods; high 
sensitivity C-reactive protein (CRP) was measured using particle enhanced 
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immunoturbidimetric assay; creatinine was measured by creatininase; and 
glycosylated hemoglobin (HbA1c) was measured using ion-exhange HPLC. Case-
control status was blinded to all laboratory staff. Two bio-samples of a given 
case-control pair were placed and tested in the same plate. The within-batch 
coefficients of variation (CVs) were 0.5-1.5% for total cholesterol, 1.1-1.4% for 
LDL-cholesterol, 0.6-0.7% for HDL-cholesterol, 0-3.9% for triglycerides, 0.5-2.3% 
for CRP, 0.6-1.1% for creatinine, 0.9-1% for HbA1c. The between-batch CVs 
were 1-1.3% for total cholesterol, 2.5-4.2% for LDL-cholesterol, 1.2-3.5% for 
HDL-cholesterol, 1.2-3.4% for triglycerides, 0.9-3.5% for CRP, 0.3-1.8% for 
creatinine, 0-1% for HbA1c.  
Measurement of plasma FAs 
Plasma FAs were measured in a targeted mode using gas chromatography-tandem 
mass spectrometry (GC-MS/MS) on Agilent 7890 GC system (Shanghai, China) 
equipped with a G7000B QQQ triple quadruple mass detector (PA, USA) and an 
auto sample injector. FAs from both free and esterified (triglycerides, 
phospholipids, cholesterol esters) fractions were measured in total. Nineteen FAs, 
covering major saturated, monounsaturated and polyunsaturated FAs, were 
quantified. Samples were analyzed in 76 batches where cases and their matched 
controls were included in the same batch. Pooled human plasma was used for 
quality control (QC) samples that were included at regular intervals (n=10) in 
each batch. Total plasma FA was calculated as the sum of the quantities of the 19 
FAs. The within-batch CVs for the measured FAs ranged from 3.4% to 14.3%, 
and the between-batch CVs ranged from 7.8% to 21.2%. 
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Measurement of plasma oxylipins 
Twelve plasma free oxylipins were measured using reversed-phase liquid 
chromatography-mass spectrometry (RPLC-MS) with Agilent 1290 ultra-pressure 
liquid chromatography (Waldbronn, Germany) coupled to electrospray ionization 
with iFunnel Technology on a triple quadrupole mass spectrometer. These 
oxylipins included: 7 AA derived oxylipins [thromboxane B2 (TXB2), leukotriene 
E4 (LTE4), 5-hydroxyeicosatetraenoic acid (5-HETE), 12-hydroxyeicosatetraenoic 
acid (12-HETE), 15-hydroxyeicosatetraenoic acid (15-HETE), 5-
ketoeicosatetraenoic acid (5-KETE), 14,15-dihydroxyeicosatrienoic acid (14,15-
DHET)]; 4 linoleic acid [LA, 18:2(n-6)] derived oxylipins [9-
hydroxyoctadecadienoic acid (9-HODE), 13-hydroxyoctadecadienoic acid (13-
HODE), 9,10-dihydroxyoctadeca(mono)enoic acid (9,10-DiHOME), 12,13-
dihydroxyoctadeca(mono)enoic acid (12,13-DiHOME)]; and 1 eicosapentaenoic 
acid [EPA, 20:5(n-3)] derived oxylipin [5-hydroxyeicosapentaenoic acid (5-
HEPE)]. The free fraction of plasma AA, a major precursor of oxylipins, was also 
assessed in the same assay. Samples were analyzed in 51 batches where cases and 
their matched controls were included in the same batch. Pooled human plasma 
was used for QC samples that were included at regular intervals (n=10) in each 
batch. The within-batch CVs for the 13 compounds ranged from 1.9% to 9.7%, 
and the between-batch CVs ranged from 7.0% to 28.9%. 
Statistical analysis 
Our nested case-control study initially included a total of 744 matched case-
control pairs. Due to lack of plasma sample, we could not obtain reliable oxylipin 
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values in 17 matched pairs of cases and controls. After exclusions of these 
participants, 727 matched case-control pairs remained for the current analysis. 
The metabolites whose intensities were zero were replaced with half of the limit 
of detection of the respective compound. Prior to any statistical analysis, we first 
performed normalization of quantitative data in three steps. First, we adjusted the 
intensity data for batch-effect. Individual FA or oxylipin intensity values were 
divided by the average intensity value of the corresponding compound in the QC 
samples for each batch. One of the low abundant oxylipins, LTE4, was not 
detected in the QC, and the geometric mean of the other 12 oxylipins in the QC 
was used as the batch-specific normalization factor instead. Second, the intensity 
values for FAs and oxylipins were converted to proportions of their respective 
total intensities. For oxylipins, this approach of using proportions of total 
intensities is less established, so sensitivity analysis was conducted on the raw 
intensities as well. In the last step, the proportions (or the raw intensities in the 
sensitivity analysis) were log-transformed, centered by mean and scaled to have a 
standard Gaussian distribution in each compound. 
We then devised a procedure to automatically group highly correlated compounds 
together to avoid multi-collinearity problem. To do this, we performed 
hierarchical clustering of the Pearson correlation matrix (agglomerative clustering 
with Euclidean distance) for the FAs and the oxylipins, respectively, using the 
data of the controls only. We determined the predictor groups using the dynamic 
tree cut procedure (220) implemented in R (221), which adaptively selects a 
sparse set of clusters given a dendrogram (clustering tree) obtained by initial 
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clustering results. Once the compounds were grouped into clusters, each cluster 
was subjected to further inspection, where it was divided into sub-clusters if their 
average pairwise correlation between the compounds was less than 0.3 within that 
cluster. In our data, the dynamic tree cut procedure reported 12 initial clusters, 
and the second-stage inspection resulted in 17 clusters: 12 for FAs and 5 for 
oxylipins. 
Given the final cluster configuration, a centroid intensity pattern for each cluster 







𝑗=1       for 𝑖 = 1, … , 𝑐  and 𝑗 =
1, … , 𝑛𝑖 
where 𝑐 denotes the total number of clusters and 𝑛𝑖 denotes the total number of 
compounds present in cluster 𝑖.  
Demographic characteristics, established cardiovascular risk factors, and plasma 
concentrations of FAs and oxylipins in the cases and controls were compared 
using univariate conditional logistic regression.  
The association between these 17 generated clusters and the risk of AMI was 
assessed using conditional logistic regression models by computing the 
multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs). In 
the multivariable model, in addition to control for the five matching factors as a 
result of the matching design and use of conditional logistic regression analysis, 
we further adjusted for age (years), hours of fasting before blood collection (<2 hr; 
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2 hr to <8 hr; ≥8 hr), education level (none; primary school; secondary school or 
above), cigarette smoking (never; ex-smoker; current smoker with <13 
cigarettes/day; current smoker with ≥13 cigarettes/day), alcohol consumption 
(g/day), physical activity (0 hr/week; <4 hrs/week of moderate and <2 hrs/week of 
strenuous activity; ≥4 hrs/week of moderate or ≥2 hrs/week of strenuous activity), 
BMI (kg/m2), history of hypertension (yes/no), and history of diabetes (yes/no). 
The regression models were compared with or without adjustment for other FA 
clusters, oxylipin clusters, and conventional cardiovascular risk factors (e.g. blood 
pressure, lipids).  
For specific FAs that showed significant attenuation after adjustment for the 
conventional cardiovascular risk factors, cross-sectional association between the 
FAs and the cardiovascular risk factors was assessed by multivariable linear 
regression among the control subjects.  
The initial data transformation, normalization, and cluster generation analyses 
were carried out using R version 3.0.3. The rest of the statistical analyses were 
conducted using Stata version 11 (StataCorp, College Station, Texas). All P 





Characteristics of the 727 incident AMI cases and 727 matched controls included 
in the current analysis are shown in Table 4-1. The mean age at blood collection 
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was 66 y (range 47-83 y) and 65% of participants were male. Participants who 
have developed AMI were more likely to be a current smoker, have no regular 
physical activity, have a higher BMI, and have history of hypertension and 
diabetes. They also tended to have higher blood pressure, LDL-cholesterol, 
triglycerides, creatinine, CRP, and HbA1c, but lower HDL-cholesterol.  
Plasma concentrations of fatty acids and oxylipins of the cases and controls were 
compared in Table 4-2. Plasma levels of stearic acid (18:0), EPA [20:5(n-3)], 
docosahexaenoic acid [DHA, 22:6(n-3)] and TXB2 were significantly lower in the 
cases than in the controls, while levels of oleic acid [cis-18:1(n-9)] and 5-KETE 
were significantly higher in the cases.  
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Table 4-1. Distribution of selected characteristics and cardiovascular risk 
factors in acute myocardial infarction cases and their matched controls 1 
  Cases Controls Pdiff
2 
N 727 727  
Age (year) 66.1 (7.9) 66.0 (7.8) NA (matched) 
Gender, % male 64.79 64.79 NA (matched) 
Education, % ≥ Secondary level 25.86 28.20 0.27 
Current smoker, % 31.09 22.28 <0.001 
Physical activity, % 0 hr/wk 3 74.42 67.40 0.004 
Body mass index (kg/m2) 23.2 (3.1) 22.9 (2.9) 0.05 
Energy intake (kcal/d) 1607 (589) 1610 (586) 0.93 
Ethanol intake, % never drinkers 79.23 75.65 0.10 
History of hypertension, % 46.77 36.73 <0.001 
History of diabetes, % 24.76 12.10 <0.001 
Cardiovascular risk factors    
Systolic blood pressure, mmHg 149.1 (23.7) 141.4 (21.7) <0.001 
Diastolic blood pressure, mmHg 83.0 (11.8) 81.1 (11.0) 0.002 
LDL-cholesterol, mmol/L 3.34 (0.87) 3.19 (0.81) 0.001 
HDL-cholesterol, mmol/L 1.29 (0.30) 1.35 (0.33) <0.001 
Triglycerides, mmol/L 1.68 (0.70) 1.57 (0.68) 0.001 
Creatinine, umol/L 70 (58-84) 68 (57-80) 0.003 
C-reactive protein, mg/L 1.5 (0.7-3.5) 1.1 (0.5-2.4) <0.001 
HbA1c, % 6.0 (5.7-7.1) 5.8 (5.5-6.2) <0.001 
1. Values are mean (SD) for normally distributed continuous variables, median 
(interquartile range) for continuous variables not normally distributed, and percent for 
categorical variables. Number of missing values: systolic & diastolic blood pressure: 85; 
triglycerides: 60; HbA1c: 2.  
2. Pdiff was derived from univariate conditional logistic regression. Variables were log 
transformed if they have skewed distribution. 
3. Only physical activities of moderate or vigorous intensity were compared. 
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Table 4-2. Distribution of plasma concentrations of fatty acids and oxylipins 
in acute myocardial infarction cases and their matched controls 1 
  Cases Controls Pdiff
2 
Plasma total fatty acids (% total) 
15:0 0.07 (0.06-0.09) 0.07 (0.06-0.09) 0.08 
16:0 20.05 (18.82-21.4) 19.88 (18.58-21.15) 0.06 
16:1(n-7) 1.76 (1.27-2.34) 1.74 (1.32-2.26) 0.86 
17:0 0.14 (0.12-0.16) 0.14 (0.12-0.16) 0.08 
17:1(n-8) 0.08 (0.06-0.09) 0.08 (0.06-0.09) 0.99 
18:0 7.32 (6.26-8.28) 7.5 (6.39-8.45) <0.001 
18:1(n-9) trans 0.05 (0.03-0.06) 0.05 (0.04-0.06) 0.13 
18:1(n-9) cis 21.81 (20.14-23.77) 21.32 (19.46-23.27) <0.001 
18:2(n-6) 36.15 (4.63) 36.41 (4.66) 0.26 
18:3(n-6) 0.19 (0.12-0.30) 0.19 (0.13-0.29) 0.61 
18:3(n-3) 0.28 (0.21-0.38) 0.29 (0.22-0.38) 0.28 
20:0 0.05 (0.04-0.06) 0.05 (0.04-0.06) 0.42 
20:1(n-9) 0.11 (0.09-0.12) 0.1 (0.09-0.12) 0.13 
20:2(n-6) 0.18 (0.16-0.21) 0.18 (0.16-0.2) 0.11 
20:3(n-3) 0.01 (0.01-0.02) 0.02 (0.01-0.02) 0.17 
20:3(n-6) 0.88 (0.67-1.14) 0.85 (0.68-1.08) 0.41 
20:4(n-6) 7.44 (6.44-8.74) 7.5 (6.47-8.73) 0.79 
20:5(n-3) 0.39 (0.31-0.49) 0.41 (0.32-0.52) <0.001 
22:6(n-3) 1.90 (1.37-2.77) 1.98 (1.42-2.98) 0.002 
Plasma free oxylipins (% total) 
Thromboxane B2 3.05 (1.33-5.06) 3.09 (1.51-5.56) 0.02 
Leukotriene E4 0.78 (0.36-1.74) 0.79 (0.35-1.83) 0.59 
5-HETE 2.89 (1.66-4.81) 2.75 (1.66-4.47) 0.44 
12-HETE 24.11 (14.03-37.56) 23.26 (13.4-35) 0.47 
15-HETE 1.23 (0.71-1.84) 1.16 (0.67-1.75) 0.29 
5-KETE 0.35 (0.12-1.15) 0.29 (0.11-0.95) 0.04 
14,15-DHET 1.72 (1.06-2.57) 1.48 (0.94-2.42) 0.06 
9-HODE 11.11 (7.90-15.25) 11.83 (8.11-16.75) 0.15 
13-HODE 14.07 (11.10-17.49) 14.52 (10.88-18.41) 0.64 
9,10-DiHOME 13.27 (8.81-19.94) 13.3 (8.68-20.09) 0.54 
12,13-DiHOME 14.25 (9.79-21.41) 14.96 (9.89-21.33) 0.96 
5-HEPE 0.87 (0.43-1.56) 0.89 (0.41-1.61) 0.70 
Free arachidonic acid (ug/ml) 0.80 (0.59-1.10) 0.79 (0.6-1.09) 0.91 
1. Values are mean (SD) for normally distributed continuous variables, or median 
(interquartile range) for continuous variables not normally distributed.  
2. Pdiff was derived from univariate conditional logistic regression. Variables were log 
transformed if they have skewed distribution. 
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Correlation structure 
As shown in the correlation heat map (Figure 4-2), both FAs and oxylipins 
showed a high degree of correlation within their respective classes. Figure 1 
illustrates the configuration of 5 oxylipin clusters (clusters 1 to 5) and 12 FA 
clusters (clusters 6 to 17), based on the automated clustering procedure (see 
Methods). Some clusters were aggregated as expected based on their common 
food sources: cluster 7 consisted of three odd-chain FAs (15:0, 17:0, 17:1) and 
eicosadienoic acid (20:2), all found in dairy products; cluster 11 included the two 
long-chain n-3 PUFAs [20:5(n-3), 22:6(n-3)] which are mainly found in fish and 
shellfish. Other clusters may reflect endogenous conversions: cluster 9 comprised 
two mid-chain n-6 PUFAs [18:3(n-6), 20:3(n-6)]; cluster 13 included two mid-
chain n-3 PUFAs [18:3(n-3), 20:3(n-3)]; and cluster 17 encompassed two 20-
carbon FAs (20:0, 20:1). The correlation among the oxylipins also reflected 
endogenous synthesis pathways: 5 of the AA-derived oxylipins were grouped into 
cluster 2 (two HETEs and LTE4) and cluster 5 (TXB2 and 12-HETE); and 4 LA-
derived oxylipins were grouped into cluster 3 (two HODEs) and cluster 4 (two 
DiHOMEs). Oxylipins derived from the same FA were themselves positively 
correlated, whereas oxylipins derived from AA and LA tended to be inversely 
correlated, which may reflect the competition for the same enzymes for oxidation. 
Interestingly, most of the correlations between FAs and oxylipins were weak and 
not statistically significant. The strongest correlation was observed between EPA 
and its oxidized product 5-HEPE (r=0.30). In contrast, plasma free AA, unlike 
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plasma total AA, was significantly correlated with four of its oxidized metabolites 
(5-HETE, 15-HETE, 14,15-DHET, 5-KETE) (Figure 4-3).  









































Figure 4-2. Correlation heat map among plasma fatty acids and oxylipins, and clusters generation from the control group 
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Figure 4-3. Network graph among fatty acids (panel A) and oxylipins (panel 
B), showing significant correlations stronger than ±0.4 
The fatty acids are expressed as % of total fatty acids; the oxylipins are expressed as % of 
total oxylipins. Red lines indicate positive correlations, and blue lines indicate negative 
correlations. The width of the connecting lines suggests the strength of correlations. 
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Overall, the multi-collinearity was considerably reduced after the compounds 
were clustered, as shown in the correlation heat map indicating the orthogonality 
of clusters (Figure 4-4). 
 
Figure 4-4. Correlation heat map among the 17 generated clusters 
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Multivariable-adjusted association with AMI risk 
Table 4-3 shows the association between plasma FA and oxylipin clusters and 
risk of AMI. In the multivariable model with adjustment for the lifestyle 
covariates (model 2), long-chain n-3 PUFAs and stearic acid were associated with 
lower risk of AMI, while oleic acid was associated with higher risk of AMI. In 
model 3, we further adjusted for all other clusters of the same category (FAs or 
oxylipins) except one major cluster with neutral effects – cluster 6 (LA) for FAs 
and cluster 1 (14,15-DHET, 5-HEPE, 5-KETE, free AA) for oxylipins – to avoid 
multi-collinearity. After adjustment for other FA clusters, similar inverse 
associations were observed for long-chain n-3 PUFAs (OR=0.67, 95% CI: 0.53-
0.84, p<0.001) and stearic acid (OR=0.65, 95% CI: 0.44-0.97, p=0.03), while the 
association for oleic acid was no longer significant. Arachidonic acid, which was 
not substantially associated with AMI risk in model 2, became significantly 
associated with higher risk of AMI after adjustment for other FA clusters 
(OR=1.25, 95% CI: 1.03-1.52, p=0.02). To explore which clusters influenced the 
changes observed from model 2 to model 3, we examined the addition of 
individual FA clusters one by one. The addition of long-chain n-3 PUFAs seemed 
to be the main contributor to the attenuation of the association for oleic acid, and 
to the strengthening of the association for AA. Among the oxylipins, only the 
cluster of TXB2 and 12-HETE was significantly associated with lower risk of 
AMI in the model with adjustment for other oxylipin clusters (model 3) (OR=0.80, 































 In the cluster 
Description2 
  
Model 1 Model 23 Model 34 
OR (95% CI) 
p-
value OR (95% CI) 
p-








1.10 (0.95, 1.28) 0.20 1.03 (0.87, 1.22) 0.73 
  
2 LTE4, 15-HETE, 5-HETE AA oxylipins 1.06 (0.93, 1.21) 0.41 1.02 (0.87, 1.18) 0.83 1.06 (0.88, 1.26) 0.55 
3 9-HODE, 13-HODE LA oxylipins 0.93 (0.82, 1.04) 0.21 0.96 (0.84, 1.10) 0.59 0.90 (0.77, 1.06) 0.21 
4 9,10-DiHOME, 12,13-DiHOME LA oxylipins 0.98 (0.87, 1.10) 0.70 0.98 (0.86, 1.13) 0.80 0.90 (0.75, 1.09) 0.28 
5 TXB2, 12-HETE AA oxylipins 0.94 (0.83, 1.06) 0.30 0.92 (0.81, 1.05) 0.23 0.80 (0.66, 0.98) 0.03 
6 18:2(n-6) linoleic acid 0.94 (0.83, 1.06) 0.29 0.97 (0.85, 1.11) 0.71 
  
7 15:0, 17:0, 17:1(n-8), 20:2(n-6) odd-chain FAs 0.93 (0.77, 1.12) 0.44 0.94 (0.77, 1.15) 0.57 1.05 (0.79, 1.38) 0.75 
8 16:1(n-7) palmitoleic acid 1.00 (0.90, 1.11) 0.97 1.04 (0.92, 1.17) 0.56 1.02 (0.87, 1.21) 0.78 
9 18:3(n-6), 20:3(n-6) GLA, DGLA 1.04 (0.92, 1.18) 0.54 1.08 (0.95, 1.24) 0.24 1.03 (0.85, 1.24) 0.77 
10 20:4(n-6) arachidonic acid 0.99 (0.88, 1.11) 0.86 1.02 (0.90, 1.15) 0.75 1.25 (1.03, 1.52) 0.02 
11 20:5(n-3), 22:6(n-3) EPA, DHA 0.70 (0.59, 0.83) <0.001 0.71 (0.59, 0.85) <0.001 0.67 (0.53, 0.84) <0.001 
12 18:1(n-9) trans trans elaidic acid 0.90 (0.80, 1.02) 0.09 0.88 (0.78, 1.01) 0.06 0.88 (0.77, 1.01) 0.06 
13 18:3(n-3), 20:3(n-3) ALA, ETE 0.88 (0.76, 1.03) 0.10 0.88 (0.75, 1.04) 0.14 0.96 (0.78, 1.18) 0.71 
14 16:0 palmitic acid 1.13 (0.99, 1.28) 0.06 1.03 (0.89, 1.18) 0.70 1.00 (0.84, 1.19) 0.98 
15 18:0 stearic acid 0.56 (0.41, 0.78) 0.001 0.66 (0.47, 0.92) 0.02 0.65 (0.44, 0.97) 0.03 
16 18:1(n-9) cis oleic acid 1.20 (1.06, 1.35) 0.003 1.14 (1.01, 1.28) 0.03 1.08 (0.93, 1.26) 0.29 
17 20:0, 20:1(n-9) 20-carbon FAs 1.05 (0.89, 1.23) 0.56 1.02 (0.85, 1.22) 0.82 1.06 (0.86, 1.31) 0.57 
1. Odds ratios (95% confidence intervals) were derived from conditional logistic regression models and expressed as per standard deviation 
increase of each cluster. The fatty acids are expressed as percentage of total fatty acids, and the oxylipins as percentage of total oxylipins.  
2. Abbreviations: AA: arachidonic acid; ALA: α-linolenic acid; DGLA: Dihomo-γ-linolenic acid; DHA: docosahexaenoic acid; EPA: 
eicosapentaenoic acid; ETE: Eicosatrienoic acid; FAs: fatty acids; GLA: γ-linolenic acid; LA: linoleic acid. 
3. The conditional logistic regression models included the following additional variables: hours of fasting before blood collection, level of 
education, cigarette smoking, alcohol consumption, physical activity, BMI, history of hypertension and diabetes. 
4. In addition to the variables described in #3, the conditional logistic regression models further included all other oxylipin clusters in models for 
clusters 2 to 5, or all other fatty acid clusters in models for clusters 7 to 17. 
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Mediation by oxylipins and cardiovascular risk factors 
The clusters which were associated with AMI risk in Table 4-3 were examined 
further by adjusting for potential biological mediators of their associations (Table 
4-4). Adjustment for oxylipin clusters did not substantially attenuate associations 
for the FA clusters. In contrast, the associations for AA and stearic acid were 
substantially attenuated after adjustment for cardiovascular risk factors including 
blood pressure, blood lipids, creatinine, CRP and HbA1c. To explore what 
specific cardiovascular risk factors may explain this attenuation, we assessed the 
cross-sectional multivariable-adjusted association between these two FAs and 
cardiovascular risk factors in the control group. AA was significantly associated 
with higher LDL-cholesterol, HDL-cholesterol, creatinine, and HbA1c, but lower 
triglycerides levels (Table 4-5). Stearic acid was marginally associated with 
lower HbA1c. 
Sensitivity analyses 
When further exploring the individual components of the clusters associated with 
AMI risk, we observed that the associations for the two long-chain n-3 PUFAs in 
cluster 11 were similar, while the association between cluster 5 (TXB2 and 12-
HETE) and risk of AMI was solely due to TXB2 (OR=0.81, 95% CI: 0.71-0.93, 
p=0.003) (Table 4-4). Sensitivity analyses using the absolute concentration of 
TXB2 instead of a proportion and with or without adjustment for other oxylipins 
showed similar significant associations (OR ranged 0.80 to 0.87, all p-
value<0.05), suggesting a robust association. TXB2 was not significantly 
associated with any of the cardiovascular risk factors (Table 4-5), and its 
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association with AMI risk was not substantially attenuated by further adjustment 



























Table 4-4. Change in associations of fatty acid and oxylipin clusters with risk of acute myocardial infarction1 when adding 
potential biological mediators 
Exposure variable2 
Model with multivariable 
factors3 
Model with Oxylipin 
clusters4 
Model with CVD risk 
factors5 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Clusters                 
10 [20:4(n-6)] AA 1.25 (1.03, 1.52) 0.02 1.22 (1.00, 1.49) 0.05 1.16 (0.93, 1.44) 0.19 
11 [20:5(n-3), 22:6(n-3)] EPA, DHA 0.67 (0.53, 0.84) <0.001 0.66 (0.53, 0.83) <0.001 0.67 (0.52, 0.86) 0.002 
15 [18:0] stearic acid 0.65 (0.44, 0.97) 0.03 0.66 (0.44, 0.98) 0.04 0.79 (0.49, 1.28) 0.33 
5 [TXB2, 12-HETE] AA oxylipins 0.80 (0.66, 0.98) 0.03     0.84 (0.67, 1.05) 0.12 
Individual compounds 
       20:5(n-3) EPA 0.74 (0.62, 0.88) 0.001 0.73 (0.61, 0.88) 0.001 0.75 (0.61, 0.91) 0.004 
22:6(n-3) DHA 0.75 (0.60, 0.93) 0.008 0.74 (0.59, 0.92) 0.007 0.71 (0.55, 0.91) 0.008 
TXB2 AA oxylipin 0.81 (0.71, 0.93) 0.003 
  
0.85 (0.73, 1.00) 0.05 
12-HETE AA oxylipin 1.00 (0.82, 1.21) 0.97     0.99 (0.79, 1.24) 0.91 
1. Odds ratios (95% confidence intervals) were derived from conditional logistic regression models and expressed as per standard deviation 
increase of exposure variables. 
2. Abbreviations: AA: arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid. 
3. Conditional logistic regression models were adjusted for the covariates listed in Model 3 of Table 4-3: hours of fasting before blood collection, 
education, cigarette smoking, alcohol consumption, physical activity, BMI, history of hypertension, history of diabetes, other fatty acid clusters (in 
models for clusters 10, 11, 15, EPA and DHA) or other oxylipin clusters (in models for cluster 5, TXB2 and 12-HETE). 
4. In addition to the variables described in #3, the conditional logistic regression models further included the five oxylipin clusters (clusters 1-5). 
5. In addition to the variables described in #3, the conditional logistic regression models further included the following additional cardiovascular 




























Table 4-5. Changes of cardiovascular risk factors on plasma concentrations of arachidonic acid, stearic acid, and thromboxane 
B2 in control subjects only 
Cardiovascular risk factors 
Arachidonic acid (cluster 10) Stearic acid (cluster 15) Thromboxane B2 
Beta 95% CI p-value Beta 95% CI p-value Beta 95% CI p-value 
Systolic blood pressure -0.01 -0.10 0.08 0.77 -0.03 -0.11 0.06 0.53 -0.02 -0.11 0.07 0.62 
Diastolic blood pressure 0.01 -0.08 0.10 0.86 0.02 -0.06 0.11 0.58 0.00 -0.09 0.09 1.00 
LDL-cholesterol 0.20 0.11 0.29 <0.001 -0.04 -0.12 0.04 0.32 0.00 -0.08 0.09 0.93 
HDL-cholesterol 0.11 0.03 0.19 0.01 0.06 -0.02 0.13 0.14 0.03 -0.07 0.12 0.58 
Triglycerides -0.09 -0.16 -0.02 0.02 0.01 -0.05 0.08 0.66 -0.03 -0.13 0.06 0.46 
Creatinine 0.09 0.01 0.17 0.03 -0.01 -0.09 0.06 0.72 0.00 -0.08 0.08 1.00 
C-reactive protein 0.00 -0.09 0.10 0.92 0.05 -0.04 0.14 0.26 -0.07 -0.16 0.02 0.13 
HbA1c 0.07 0.00 0.14 0.04 -0.06 -0.12 0.00 0.07 0.00 -0.07 0.06 0.92 
1. Values are standardized beta coefficients and their 95% confidence intervals from linear regression, expressed as the multiples of SD change in 
outcome variables (cardiovascular risk factors) corresponding to per SD increase of respective exposure variables (arachidonic acid, stearic acid, 
or thromboxane B2). 
2. Multivariable linear regression models were adjusted for the following covariates: age, gender, father’s dialect, year of birth, year of recruitment, 
and year of blood collection, hours of fasting before blood collection, education, cigarette smoking, alcohol consumption, physical activity, BMI, 
history of hypertension and diabetes, other fatty acid clusters (in models for arachidonic acid or stearic acid) or other oxylipin clusters (in models 
for thromboxane B2). 
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4.4 DISCUSSION 
In this prospective nested case-control study of Singapore Chinese, we observed 
an inverse association between long-chain n-3 PUFAs and stearic acid with risk of 
AMI, and a direct association for AA in the multivariable model with adjustment 
for other FA clusters. These associations seemed to be partly mediated by some of 
the well-established cardiovascular risk factors. We also observed a significant 
inverse association between TXB2, an AA-derived oxylipin, and risk of AMI, and 
this association was not substantially attenuated by other cardiovascular risk 
factors.  
The relation between long-chain n-3 PUFAs and CHD has been extensively 
examined in previous studies, most of which supported our observation (222). In 
contrast, previous studies that were conducted in western populations found no 
association or a positive association between circulating stearic acid and CHD 
(30). In a Japanese study, the only other study conducted in Asia, plasma stearic 
acid was inversely associated with major coronary events (223), which was 
consistent with our findings. The disparity in findings for western versus Asian 
populations may reflect differences in dietary sources of stearic acid. Stearic acid 
is highly correlated with other saturated fatty acids (SFAs) in western diet because 
they share the same predominant food sources such as red meat (224). It is 
therefore difficult to distinguish the effect of stearic acid from other SFAs in a 
western diet, which may explain the detrimental effect of stearic acid observed in 
most western populations. The major food source of SFAs in Singapore diet is 
plant-based cooking oil rather than red meat or dairy products (109). In our study, 
the correlation between plasma stearic acid with other even-chain SFAs (r range 
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0.14 to 0.20) was much weaker than that observed in previous studies conducted 
in western countries. With such low correlations with other SFAs, the effect of 
stearic acid could be investigated individually in our data, which suggested an 
inverse association with AMI risk. A lack of detrimental effects of stearic acid or 
even possible benefits are suggested by feeding trials that showed that stearic acid 
does not raise serum cholesterol levels nor impair insulin sensitivity as compared 
with carbohydrates or monounsaturated fatty acids (225, 226). 
Adipose tissue AA was associated with higher risk of AMI in two case-control 
studies in Costa Rica and Israel (227, 228), which is consistent with our 
observation for plasma AA. In most other previous studies, no association or an 
inverse association between AA biomarkers and CHD was observed (30, 229). 
One interesting observation in our analysis is that AA only became significantly 
associated with a higher AMI risk after adjustment for other FA clusters. 
Although we tried to make our variables as orthogonal as possible by the 
clustering approach, there may still be residual correlations among the clusters, 
such that the associations with AMI will change when all FA clusters were 
included in the same model. Confounding by other FAs could arise if they share 
similar food sources or if their food sources tend to be part of the same dietary 
pattern. It is therefore important to consider such confounding by other FAs in 
studies of circulating FAs and health outcomes. 
There have been concerns about LA intake as it may be converted to AA 
endogenously and AA may increase levels of detrimental oxylipins which 
increase blood pressure and inflammation (97, 98). Our results suggest that these 
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effects are more complex than previously thought. Our data suggest that plasma 
LA is not associated with AMI risk, and LA is not strongly associated with higher 
AA levels (r=-0.06). Indeed, wide variations of dietary LA intake do not affect 
tissue AA concentrations substantially in a meta-analysis of feeding trials (230). 
Therefore, it is unlikely that dietary LA increases risk of AMI through conversion 
to AA. Furthermore, we could not identify potential detrimental effects of AA 
through increased production of oxylipins. The cardiovascular risk factors that 
AA was associated with were not the ones plausibly affected by oxylipins, either. 
Besides the commonly known pro-inflammatory and pro-aggregatory metabolites 
such as the leukotrienes and thromboxanes, AA is also the precursor to other anti-
inflammatory or vasodilating metabolites such as the lipoxins (231) and EETs 
(113). It is therefore difficult to predict the net impact of the entire AA 
metabolome, likely depending on the differential enzymatic activity for the 
synthesis of metabolites as well as the interactions among the metabolites (69). 
Hence the mechanism behind the direct association between AA and AMI risk is 
not entirely accounted for by the synthesis of pro-inflammatory oxylipins, and 
remains elusive. 
Not all associations found in this study were consistent with our expectation. The 
pro-thrombotic oxylipin TXA2 functions as a transient autocrine, and its 
biological inactive metabolite TXB2 has been used to indirectly measure TXA2 
production (232). The other oxylipin grouped in the same cluster with TXB2, 12-
HETE, has also been shown to be pro-thrombotic in platelets (114, 233). Contrary 
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to our expectation, the cluster with these two oxylipins was inversely associated 
with AMI risk in our study, which requires further study in the future. 
We did not observe substantial association between other oxylipin clusters and 
AMI risk besides TXB2. The autocrine and short-lived nature of these oxylipins 
might account for these observations. The oxylipins may impose important pro- or 
anti-inflammatory effects on platelets, leukocytes, and endothelial cells, but such 
changes often occur locally rather than systemically, and temporarily rather than 
long-term. The blood samples of our study participants were collected years prior 
to the onset of AMI, while the biological changes of oxylipins could have taken 
place at a much later stage. Therefore, it is not surprising that we did not detect 
many associations with a single time-point prospective assessment of plasma 
oxylipins. Our results also suggest that the studied plasma free oxylipins may not 
be good biomarkers to predict risk of AMI in long term, although it remains to be 
examined if the oxylipins within the esterified pool of lipoprotein particles may 
have implications in cardiovascular risk. The correlations between most plasma 
FAs and oxylipins were generally weak, which suggests that the levels of 
oxylipins may be more dependent on the enzyme activity required for the 
conversions than the levels of FA precursors. 
To our knowledge, our study is the first prospective study of a wide range of 
oxylipins in relation to AMI risk. In addition, it is one of the largest studies of 
fatty acid biomarkers and AMI in Asia. The values we obtained for FAs and 
oxylipins were within the range of those reported in earlier studies, suggesting a 
reliable quantification. Furthermore, the clustering among various FAs and 
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oxylipin families was as expected based on biological knowledge, suggesting that 
our analysis approach was sound. However, our study also has several potential 
limitations. First, there may be misclassifications in the measurement of plasma 
FAs and oxylipins. For example, we only included measurements of FAs and 
oxylipins at a single point in time, which may not best capture the long-term 
dietary and physiological status of our study participants. However, 
misclassifications of long-term FA and oxylipin status were likely to be non-
differential which may lead to attenuated associations. Second, we measured the 
major oxylipins in plasma rather than the full spectrum of them. Other oxylipins 
that we did not examine in this study might play a more significant role in 
mediating certain FAs. Third, as an observational study, there might be residual 
confounding by other unmeasured biomarkers, genetic or behavioral risk factors. 
Fourth, our results may have been affected by multiple testing as we examined 17 
clusters as exposure variables. Using Bonferroni correction (alpha=0.05/17=0.003) 
the association for long-chain n-3 PUFA remains statistically significant, whereas 
associations for stearic acid, arachidonic acid, and the cluster including TXB2 
were only nominally significant. This highlights the need to confirm these 
findings in an independent study population. Last, caution should be taken to 
generalize our findings to other populations. 
In summary, we measured a wide range of FAs and oxylipins, and clustered the 
molecules based on their correlation structure to reduce the multi-collinearity in 
the regression analysis. The resulting clusters were consistent with shared dietary 
sources and endogenous metabolic pathways. Plasma long-chain n-3 PUFAs and 
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stearic acid were associated with a lower risk of AMI and plasma total AA was 
associated with higher risk of AMI. The non-typical findings for stearic acid and 
AA may suggest the importance of examining these FAs in non-western 
populations with different dietary structures and/or the importance of adjusting for 
other FAs. Plasma concentration of the oxylipin TXB2 was inversely associated 
with risk of AMI. This association was unexpected as TXB2 is a marker for the 
pro-thrombotic TXA2, and this finding warrants further investigation in other 
prospective studies. Our results suggest that the examined oxylipins were not 
critical mediators of the relation between fatty acids and AMI risk, but we cannot 
exclude the possibility that oxylipins that we did not measure play a greater role. 
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CHAPTER 5. STUDY III: OMEGA-3 FATTY ACIDS 
AND ACUTE MYOCARDIAL INFARCTION 
This chapter was based on the following manuscript: 
Sun Y, Koh WP, Yuan JM, Choi H, Su J, Ong CN, and van Dam RM*. Plasma 
alpha-linolenic and long-chain omega-3 fatty acids were associated with a lower 
risk of acute myocardial infarction in Singapore Chinese adults. J Nutr 2016;146. 
Advance online publication. doi: 10.3945/jn.115.220418 
 
5.1 INTRODUCTION 
Coronary heart disease (CHD) is one of the leading causes of death worldwide, 
and the disease burden is increasing rapidly in Asia in recent years (153, 154, 
234). Dietary fatty acids, among other modifiable lifestyle factors, have been 
implicated in the etiology of CHD. Omega-3 polyunsaturated fatty acids (n-3 
PUFAs) have been associated with lower risk of cardiovascular diseases, 
particularly fatal CHD (235). There are two major subtypes of n-3 PUFAs: the 
marine-originated long-chain n-3 PUFAs eicosapentaenoic acid (EPA, 20:5 n-3) 
and docosahexaenoic acid (DHA, 22:6 n-3); and the plant-derived intermediate-
chain n-3 PUFA alpha-linolenic acid (ALA, 18:3 n-3) found mainly in nuts, seeds, 
and their oils. Dietary and circulating long-chain n-3 PUFAs have been shown to 
be inversely associated with fatal and nonfatal CHD in large prospective studies 
(74, 78). In some clinical trials long-chain n-3 PUFAs administration reduced 
total mortality and CHD incidence (79, 80), but other trials did not suggest 
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beneficial effects (77). The relationship between ALA and CHD risk has been 
examined in fewer studies than long-chain n-3 PUFAs. ALA can be utilized for 
the production of EPA and DHA in the body through desaturase and elongase 
enzymes, and may also affect CHD risk independently (87). Findings of limited 
epidemiological studies supported a beneficial effect of ALA intake on nonfatal 
or fatal CHD, particularly sudden death (25, 88-91), whereas others reported no 
beneficial or even detrimental effects on cardiovascular health (92, 93). 
Most studies on n-3 PUFAs and risk of CHD have been conducted in western 
populations. Food sources, levels of intake, and physiological responses may be 
different for Asian people from their western counterparts. Few studies have 
examined dietary (91, 236-241) or circulating (223, 242) long-chain n-3 PUFAs 
in relation to cardiovascular diseases in Asian populations. Furthermore, most 
studies focused on CHD mortality. Data on ALA in Asia has been sparse (91), 
and there has not been any prospective study on plasma ALA and CHD risk.  
EPA and DHA have been suggested to affect cardiovascular risk through a variety 
of cardio-metabolic pathways, including reduction in serum triglycerides and 
blood pressure (77, 235). ALA has shown beneficial effects on platelet function, 
arterial compliance, and arrhythmia (95). To date, there has been limited data on 
the effect of n-3 PUFAs on biological markers for cardiovascular disease risk in 
population based studies.  
Therefore, we conducted a case-control study nested within an established 
population-based prospective cohort, the Singapore Chinese Health Study, to 
examine the association between plasma n-3 PUFAs, including ALA, EPA and 
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DHA, and risk of acute myocardial infarction (AMI), which has the highest 
morbidity and mortality among the clinical spectrum of CHD (243). In addition, 
we examined the possible mediation of the effects of these n-3 PUFAs via 
established cardiovascular risk factors including blood lipids, blood pressure, and 
inflammation. 
5.2 METHODS 
Singapore Chinese Health Study 
The Singapore Chinese Health Study (SCHS) is a population-based, prospective 
cohort study of 63,257 Chinese men and women (Hokkien or Cantonese dialect 
group) aged 45-74 years residing in public housing estates, where 86% 
Singaporeans resided at the time of recruitment. Recruitment and assessment of 
baseline diet, lifestyle, and medical history took place from 1993 to 1998. To date, 
follow-up surveys have been conducted twice (1999-2004; 2006-2010) to update 
information on use of tobacco and alcohol use, medical history, and menopausal 
status. Blood specimens were also collected from 28,439 subjects during 1994-
2005. The cohort has been followed up for morbidity and mortality through 
record linkage with Singapore Registry of Births and Deaths, Hospital Discharge 
Database, and Singapore Cancer Registry. This study was approved by the 
Institutional Review Board at the National University of Singapore, and all 
participants gave informed consent. 
Nested case-control study 
We have established a nested case-control study involving 744 incident AMI 
cases and 744 matched controls. These cases and controls were selected from the 
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SCHS participants who provided blood and did not have a history of CHD or 
stroke at the time of blood collection based on self-reported diagnosis and data 
from the Hospital Discharge Database [International Classification of Diseases 
(ICD)-9 codes: 410-414,427,428, 430-434, 438]. 
Cases include incident nonfatal or fatal AMI occurring after blood specimen 
collection up until 31 December 2010. We identified and verified cases of AMI 
through linkage with three databases: 1) The national Mediclaim System Hospital 
Discharge Database (HDD), which has been in use in Singapore since 1990 and 
records up to 3 diagnoses per patient for inpatient discharges from public and 
private hospitals based on ICD-9 (217). We selected all participants who were 
identified as AMI cases (ICD-9: 410) in this database until 31 December 2010. 
The medical records of these participants were then reviewed by a cardiologist 
using the criteria of the Multi-Ethnic Study of Atherosclerosis (MESA) (218) and 
only confirmed cases of AMI were included in our study. 2) The Singapore 
Myocardial Infarction Registry (SMIR). SMIR is a centralized population-based 
registry that uses similar procedures as we used for HDD to confirm AMI based 
on a review of medical records (216). We only had access to cases up to 31 
December 2005 from SMIR, but these cases largely overlapped with the cases 
identified through the other databases. Through steps 1 and 2, 555 incident AMI 
cases were identified. 3) The Singapore Registry of Births and Deaths. This 
registry codes causes of death according to ICD-9, and participants with codes 
410-414 (ischemic heart disease) stated as the primary cause of death were 
selected, which are assumed to be death from myocardial infarction in practice, 
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giving 289 fatal AMI cases until 31 December 2010. Among them, 100 belonged 
to incident AMI cases described above. We thus identified 744 unique fatal and 
nonfatal AMI cases. 
Controls were selected using the risk-set sampling strategy (219): controls were 
participants who were alive and free of CHD at the time of the diagnosis or death 
of the respective indexed cases and matched (in 1-to-1 ratio) for sex, father’s 
dialect group, date of birth (± 2 years), date of recruitment (± 1 year) and date of 
blood collection (± 6 months). 
Assessment of dietary intakes and relevant covariates 
All data on diet and lifestyle were collected using a validated 165-item semi-
quantitative food frequency questionnaire (FFQ). Intakes of dietary nutrients were 
calculated using the Singapore food composition table (213). The FFQ has been 
validated by two 24-h dietary recalls and re-administration of the FFQ. The 
correlation coefficients between these two methods for fat-related nutrients 
ranged from 0.24 to 0.79 (213). The intakes of n-3 PUFAs from marine / non-
marine sources, and their major food sources were calculated. The major dietary 
sources of long-chain n-3 PUFAs (mainly EPA and DHA) were listed in 14 
seafood items in the FFQ, including fresh fish (fish ball or cake, deep fried fish, 
pan or stir fried fish, boiled or steamed fish), fresh shellfish (shrimp or prawn, 
squid or cuttlefish), dried/salted fish (salted fish, ikan bilis, dried fish, other dried 
seafoods such as dried shrimp, dried oyster, dried cuttlefish), and canned fish 
(canned tuna, canned sardine) (244). The main dietary sources of intermediate-
chain n-3 PUFAs (mainly ALA) were grains (21%), cooking oils (11%), legumes 
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and soy (9%) (91). Information on education, body mass index (BMI), physical 
activity, smoking and alcohol intake, and history of diabetes and hypertension 
were collected as previously described (214-216).  
Assessment of cardiovascular risk factors 
Blood samples were collected during home visits during 1994-2005 and stored at 
-80°C. Systolic and diastolic blood pressure was measured by Omron blood 
pressure monitors three times using a standard protocol and the average of the 
three measurements was used for statistical analysis. Conventional biochemical 
risk factors of CHD were measured by National University Hospital referral 
laboratories. Total, HDL and LDL (directly measured) cholesterol and 
triglycerides were measured using enzymatic, calorimetric methods; high 
sensitivity C-reactive protein (CRP) was measured using particle enhanced 
immunoturbidimetric assay; creatinine was measured by creatininase; and 
glycosylated hemoglobin (HbA1c) was measured using ion-exhange HPLC. Case-
control status was blinded to all laboratory staff. Two bio-samples of a given 
case-control pair were placed and tested in the same plate. The within-batch CVs 
were 0.5-1.5% for total cholesterol, 1.1-1.4% for LDL-cholesterol, 0.6-0.7% for 
HDL-cholesterol, 0-3.9% for triglycerides, 0.5-2.3% for CRP, 0.6-1.1% for 
creatinine, 0.9-1% for HbA1c. The between-batch CVs were 1-1.3% for total 
cholesterol, 2.5-4.2% for LDL-cholesterol, 1.2-3.5% for HDL-cholesterol, 1.2-3.4% 
for triglycerides, 0.9-3.5% for CRP, 0.3-1.8% for creatinine, 0-1% for HbA1c.  
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Measurement of plasma fatty acids 
Plasma fatty acids were measured using gas chromatography-tandem mass 
spectrometry (GC-MS/MS) on an Agilent 7890 GC system (Shanghai, China) 
equipped with a 7001B QQQ triple quadruple mass detector (PA, USA) and an 
auto sample injector. Using this method, fatty acids from both free and esterified 
(triglycerides, phospholipids, cholesterol esters) fractions were measured in total. 
Nineteen fatty acids, covering major saturated, monounsaturated and 
polyunsaturated fatty acids, were quantified. Total plasma fatty acids was 
calculated as the sum of the quantities of the 19 fatty acids. The within-batch 
variations of coefficients (CVs) for the 3 fatty acids of interest (ALA, EPA, DHA) 
ranged from 5.3% to 8.1%, and the between-batch CVs ranged from 12.2% to 
16.8%. 
Statistical analysis 
Individual fatty acids were expressed as a percentage of total plasma fatty acids. 
Corresponding fatty acid intakes were expressed as a percentage of total energy 
intake. Uni-variate distributions were assessed on all continuous variables. Plasma 
ALA, EPA, DHA, creatinine, CRP, and HbA1c were log transformed to improve 
normality. The continuous variables were categorized into quartiles according to 
the distribution among the control subjects.  
Demographic characteristics and cardiovascular risk factors were compared 
between the cases and controls using univariate conditional logistic regression. 
Cross-sectional associations between plasma fatty acids and various 
cardiovascular risk factors were assessed by multivariable linear regression 
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among the control subjects with unique individuals. To improve the comparability 
across different risk factors, all fatty acids and risk factors were standardized to z-
scores (245), and standardized beta coefficients were presented.  
Conditional logistic regression models were used to compute multivariable-
adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for higher quartiles 
of the exposure variables using the lowest quartile as the reference group. Tests 
for trend were evaluated by modeling the medians of each quartile of exposure 
variables as continuous variables. In the multivariable model, besides the five 
matching factors, we adjusted for age (years), total energy intake (kCal/day), total 
plasma fatty acids (mg/L), hours of fasting before blood collection (<2 hr; 2 hr to 
<8 hr; >=8 hr), education level (none; primary school; secondary school or above), 
cigarette smoking (never; ex-smoker; current smoker with <13 cigarettes/day; 
current smoker with ≥13 cigarettes/day), alcohol consumption (g/day), physical 
activity (0 hr/week; <4 hrs/week of moderate and <2 hrs/week of strenuous 
activity; ≥4 hrs/week of moderate or ≥2 hrs/week of strenuous activity), BMI 
(kg/m2), cholesterol intake (mg/d, residual adjusted), fiber intake (g/d, residual 
adjusted), total fat intake (% total energy), history of hypertension, and history of 
diabetes. Analyses were conducted for plasma and dietary n-3 PUFAs as well as 
fish consumption. The sum of the standardized z-scores (245) of plasma and 
dietary n-3 PUFAs were also examined as an integrated measure of exposure. 
Analyses were also repeated separately for fatal and nonfatal AMI cases. 
The possible mediation effect of plasma n-3 PUFAs on AMI risk through various 
established cardiovascular risk factors was assessed by comparing the extreme-
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quartile ORs of n-3 PUFAs with or without each of the potential mediators in the 
fully adjusted model. The percentage of total effect that is mediated by each risk 
factor was calculated as the percentage change in the beta-coefficient of the fatty 
acids, and the level of significance (p-value) of such mediation effect were 
evaluated using the Karlson-Holm-Breen (KHB) method (246). We also assessed 
the combined mediation effect of all the risk factors by including them in the 
KHB mediation model together. Several risk factors had missing values. Blood 
pressure was not measured for 87 subjects. As only non-fasting blood was 
collected, the plasma triglycerides level was beyond the limit of detection for 62 
samples. Two participants lacked HbA1c information because no red blood cell 
sample was available. In order to compare the mediation effect using the same 
group of subjects, the above-mentioned missing values were imputed for the 
mediation analyses by fitting a linear regression equation with age, gender, BMI, 
and other cardiovascular risk factors without missing values (LDL and HDL-
cholesterol, creatinine and CRP). 
All statistical analyses were conducted using Stata version 11 (StataCorp, College 
Station, Texas), and statistical significance was set as p-value < 0.05. 
 
5.3 RESULTS 
We selected 744 AMI cases and 744 of their matched controls. The mean age at 
blood collection was 66 years (ranged 47-83 years) and 65% of participants were 
male. Participants who developed AMI were more likely to have lower level of 
education but a higher level of BMI, to be a current smoker, to have less regular 
physical activity, and to have a history of physician-diagnosed hypertension and 
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diabetes. They also tended to have higher blood pressure, LDL-cholesterol, 
triglycerides, creatinine, CRP, and HbA1c, but lower HDL-cholesterol. The AMI 
cases had significantly lower plasma levels of EPA and DHA as compared with 
the controls, but the difference in ALA was not significant (Table 5-1).  
Table 5-2 shows the distributions of selected characteristics in relation to 
quartiles of plasma n-3 PUFAs among controls. Participants in the highest quartile 
of ALA were more likely to have higher education, to be non-smokers, to have no 
regular physical activity, and to have higher intake of dietary ALA. Those in the 
highest quartile of long-chain n-3 PUFAs (EPA+DHA) were more likely to be 
females and to have higher intake of dietary long-chain n-3 PUFAs. The 
correlation coefficient between plasma and dietary n-3 PUFAs was 0.21 
(p<0.0001) for EPA/DHA, and 0.11 (p=0.003) for ALA. These moderate 
correlations were as expected since the dietary assessment was conducted 6.6 
years before blood collection on average. 
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Table 5-1. Distributions of selected characteristics in patients who developed 
incidental AMI and the their matched control subjects1 
Characteristics, unit Cases Controls Pdiff 2  
N 744 744  
Age, years 66.08 (7.81) 65.97 (7.74) NA (matched) 
Gender, % male 64.65 64.65 NA (matched) 
Education, % ≥ secondary level 25.94 28.23 0.28 
Current smoker, % 31.05 21.91 <0.001 
Physical activity, % 0 hr/wk 3 74.60 67.20 0.002 
Body mass index, kg/m2 23.17 (3.12) 22.86 (2.91) 0.06 
Energy intake, kcal/day 1605.6 (590.7) 1610.1 (587.9) 0.87 
Ethanol intake, % never drinkers 79.17 75.94 0.14 
History of hypertension, % 46.91 36.83 <0.001 
History of diabetes, % 25.00 12.50 <0.001 
Alpha-linolenic acid, % 0.33 (0.20) 0.34 (0.28) 0.40 
Eicosapentaenoic acid, % 0.44 (0.25) 0.52 (0.43) <0.001 
Docosahexaenoic acid, % 2.24 (1.24) 2.42 (1.45) 0.001 
Systolic blood pressure, mmHg 149.03 (23.70) 141.40 (21.67) <0.001 
Diastolic blood pressure, mmHg 83.05 (11.73) 81.12 (10.92) 0.001 
LDL-cholesterol, mmol/L 3.34 (0.87) 3.20 (0.82) 0.001 
HDL-cholesterol, mmol/L 1.28 (0.30) 1.35 (0.32) <0.001 
Triglycerides, mmol/L 1.68 (0.69) 1.57 (0.68) 0.001 
Creatinine, umol/L 77.22 (57.02) 71.21 (37.11) 0.03 
C-reactive protein, mg/L 3.79 (9.10) 2.79 (9.14) 0.05 
HbA1c, % 6.66 (1.64) 6.13 (1.11) <0.001 
1Values are mean (SD) for continuous variables and percent for categorical variables. 
Number of missing values: systolic & diastolic blood pressure: 87; triglycerides: 62; 
HbA1c: 2.  
2Pdiff was derived from univariate conditional logistic regression. 

























Table 5-2. Distributions of selected characteristics by quartile levels of plasma n-3 PUFAs among control subjects only1 
Characteristics, unit Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend2 
N 186 186 186 186  
Plasma ALA      
Median 0.19% 0.25% 0.33% 0.49%  
Age, years 66.54 (7.12) 65.83 (7.71) 66.35 (8.33) 65.16 (7.74) 0.31 
Gender, % male 62.37 66.67 68.82 60.75 0.33 
Education, % secondary & above 17.20 29.03 29.03 37.63 <0.001 
Current smoker, % 30.11 22.58 23.66 11.29 <0.001 
Physical activity, % 0 hr/wk 3 76.88 67.20 66.67 58.06 0.002 
Body mass index, kg/m2 22.56 (2.79) 22.73 (2.93) 23.26 (2.88) 22.91 (3.01) 0.1163 
Energy intake, Kcal/d 1623.23 (595.65) 1566.38 (588.29) 1645.13 (571.62) 1605.52 (597.44) 0.6173 
Ethanol intake, g/d 2.76 (8.60) 2.73 (7.77) 1.92 (7.13) 1.93 (8.45) 0.5786 
History of hypertension, % 36.56 36.02 37.10 37.63 0.99 
History of diabetes, % 8.06 13.44 12.37 16.13 0.125 
Dietary ALA, %kcal 0.30 (0.12) 0.30 (0.12) 0.33 (0.16) 0.37 (0.19) <0.0001 
Plasma EPA+DHA  
Median 1.50% 2.09% 2.84% 4.83%  
Age, years 65.39 (8.00) 66.34 (7.75) 65.52 (7.60) 66.64 (7.59) 0.32 
Gender, % male 68.82 70.43 56.45 62.90 0.02 
Education, % secondary & above 31.18 26.88 30.11 24.73 0.49 
Current smoker, % 27.96 22.04 18.82 18.82 0.11 
Physical activity, % 0 hr/wk 3 70.97 65.59 69.89 62.37 0.261 
Body mass index, kg/m2 22.78 (2.91) 22.96 (3.08) 22.68 (2.69) 23.04 (2.95) 0.6226 
Energy intake, Kcal/d 1607.65 (602.78) 1661.30 (648.18) 1600.48 (581.74) 1570.83 (511.62) 0.5145 
Ethanol intake, g/d 2.01 (6.77) 1.91 (6.12) 2.44 (8.79) 2.97 (9.80) 0.5656 
History of hypertension, % 32.26 33.87 40.32 40.86 0.2 
History of diabetes, % 12.37 11.83 15.05 10.75 0.635 
Dietary EPA+DHA, %kcal 0.16 (0.09) 0.19 (0.08) 0.19 (0.08) 0.21 (0.10) <0.0001 
1Values are mean (SD) for continuous variables and percent for categorical variables. The fatty acids are expressed as % of total plasma fatty acids. 
Abbreviations: ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; EPA+DHA: sum of plasma EPA and DHA; DHA: docosahexaenoic acid; 
PUFA: polyunsaturated fatty acid.  
2Ptrend was derived from one-way ANOVA (for continuous characteristics) or chi2 test (for categorical charateristics).  
3Only physical activities of moderate or vigorous intensity were compared. 
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Cross-sectional associations between plasma n-3 PUFAs and cardiovascular risk 
factors in the control group were assessed using multivariable linear regression 
and presented in Table 5-3. ALA was significantly associated with lower systolic 
and diastolic blood pressure, lower LDL and HDL-cholesterol concentrations and 
with higher triglyceride concentrations. EPA was significantly associated with 
higher HDL-cholesterol and DHA was significantly associated with higher LDL-
cholesterol and triglyceride concentrations. With Bonferroni correction for 
multiple comparisons, the threshold for statistical significance is 0.05/32=0.0016. 
The association for ALA with reduced LDL cholesterol, reduced HDL cholesterol, 
and higher triglycerides remained statistically significant, while the other 
associations became insignificant. 
Table 5-3. The changes of cardiovascular risk factors on plasma 
concentrations of n-3 PUFAs in control subjects only1-4 
Cardiovascular risk factors Unit ALA EPA DHA EPA+DHA 
Systolic blood pressure mmHg -0.10(0.04)* -0.03(0.04) -0.02(0.04) -0.03(0.04) 
Diastolic blood pressure mmHg -0.12(0.04)** -0.05(0.04) -0.06(0.04) -0.07(0.04) 
LDL-cholesterol mmol/L -0.22(0.04)*** 0.06(0.04) 0.08(0.04)* 0.08(0.04)* 
HDL-cholesterol mmol/L -0.19(0.04)*** 0.11(0.04)** 0.07(0.04) 0.08(0.04)* 
Triglycerides mmol/L 0.26(0.03)*** 0.02(0.03) 0.07(0.03)* 0.06(0.03)* 
Creatinine umol/L -0.05(0.03) -0.06(0.03) -0.04(0.03) -0.04(0.03) 
C-reactive protein mg/L -0.07(0.04) -0.05(0.04) -0.05(0.04) -0.06(0.04) 
HbA1c % -0.05(0.03) -0.02(0.03) -0.01(0.03) -0.02(0.03) 
1Values are standardized beta coefficient (SE) from linear regression, expressed as the 
multiples of SD change in outcome variables (cardiovascular risk factors) per SD 
increase of logged values of respective exposure variables (plasma n-3 PUFAs). Due to 
skewed distribution, creatinine, CRP, and HbA1c were log transformed before being 
standardized.  
2All models were adjusted for age at blood collection, gender, father’s dialect, date of 
blood collection, total energy intake, total plasma fatty acids, hours of fasting before 
blood collection, education, cigarette smoking, alcohol consumption, physical activity, 
BMI, cholesterol intake, fiber intake, total fat intake, and history of hypertension and 
diabetes. Number of missing values in the regression: systolic & diastolic blood pressure: 
42; triglycerides: 26; HbA1c: 2; 723 unique individuals were used for the other analyses.  
3Abbreviations: ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; EPA+DHA: 
sum of plasma EPA and DHA; DHA: docosahexaenoic acid; PUFA: polyunsaturated 
fatty acid.  
4Levels of significance: *: p<0.05, **: p<0.01, ***: p<0.001. 
Chapter 5. Study III: Omega-3 fatty acids and AMI 
- 106 - 
 
Table 5-4 shows the association between plasma n-3 PUFAs and risk of AMI. In 
the multivariable model, higher levels of EPA and DHA were monotonically 
associated with a lower AMI risk. As compared with the lowest quartile, the OR 
for the highest quartile was 0.68 (95% CI: 0.46-1.00, p-trend=0.02) for EPA, 0.59 
(95% CI: 0.38-0.90, p-trend=0.01) for DHA, and 0.62 (95% CI: 0.41-0.94), p-
trend=0.03) for the combined level of EPA and DHA. For ALA, no clear trend 
was observed: the higher three quartiles of ALA were associated with lower risk 
of AMI as compared with the lowest quartile, a difference that was significant for 
the third quartile. Similar trends were observed for dietary intake of long-chain n-
3 PUFAs (extreme-quartile OR=0.64, 95% CI: 0.46, 0.89), but no substantial 
association was observed for dietary intake of ALA (Table 5-5). We also 
conducted separate analyses for fatal and nonfatal AMI as an outcome. The 
inverse association for plasma ALA tended to be more pronounced for fatal AMI 
(extreme-quartile OR=0.62, 95% CI: 0.34-1.11) than for nonfatal AMI (extreme-
quartile OR=0.80, 95% CI: 0.52-1.24), but this was not observed for plasma EPA 

























Table 5-4. Odds ratios (95% CIs) of acute myocardial infarction by quartile levels of plasma n-3 PUFAs1  
Plasma n-3 PUFA Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend 
ALA           
N(cases/total) 220/406 173/359 167/353 184/370  
median 0.19% 0.25% 0.33% 0.50%  
Model 1 1.00 0.74 (0.55, 1.00) 0.65 (0.47, 0.89) 0.68 (0.49, 0.94) 0.01 
Model 2 1.00 0.77 (0.56, 1.04) 0.67 (0.48, 0.93) 0.76 (0.54, 1.08) 0.09 
Model 3 1.00 0.75 (0.55, 1.04) 0.68 (0.48, 0.95) 0.73 (0.51, 1.05) 0.07 
EPA      
N(cases/total) 211/398 233/418 153/339 147/333  
median 0.28% 0.37% 0.46% 0.71%  
Model 1 1.00 1.12 (0.82, 1.53) 0.68 (0.48, 0.97) 0.65 (0.45, 0.93) 0.004 
Model 2 1.00 1.13 (0.82, 1.55) 0.74 (0.51, 1.06) 0.71 (0.49, 1.03) 0.03 
Model 3 1.00 1.06 (0.76, 1.48) 0.70 (0.48, 1.02) 0.68 (0.46, 1.00) 0.02 
DHA      
N(cases/total) 209/395 184/370 198/384 153/339  
median 1.18% 1.69% 2.37% 3.96%  
Model 1 1.00 0.86 (0.64, 1.17) 0.85 (0.62, 1.17) 0.56 (0.37, 0.84) 0.005 
Model 2 1.00 0.92 (0.67, 1.26) 0.91 (0.66, 1.26) 0.60 (0.40, 0.91) 0.02 
Model 3 1.00 0.90 (0.65, 1.23) 0.86 (0.61, 1.20) 0.59 (0.38, 0.90) 0.01 
EPA+DHA      
N(cases/total) 208/394 181/367 201/387 154/340  
median 1.49% 2.07% 2.83% 4.58%  
Model 1 1.00 0.86 (0.63, 1.17) 0.88 (0.64, 1.22) 0.60 (0.41, 0.89) 0.01 
Model 2 1.00 0.91 (0.66, 1.24) 0.94 (0.67, 1.31) 0.66 (0.44, 0.99) 0.04 
Model 3 1.00 0.88 (0.63, 1.21) 0.87 (0.62, 1.23) 0.62 (0.41, 0.94) 0.03 
1Values are odds ratio (95% CI) from conditional logistic regression. The fatty acids are expressed as % of total plasma fatty acids. Abbreviations: 
ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; EPA+DHA: sum of plasma EPA and DHA; DHA: docosahexaenoic acid; PUFA: 
polyunsaturated fatty acid. Model 1 was adjusted for total energy intake, age at blood collection, total plasma fatty acids, hours of fasting before 
blood collection, gender, father’s dialect, year of birth, year of recruitment, and year of blood collection. Model 2 was further adjusted for 
education, cigarette smoking, alcohol consumption, physical activity, BMI, cholesterol intake, fiber intake, and total fat intake. Model 3 was 

























Table 5-5. Odds ratios (95% CIs) of acute myocardial infarction by quartiles of dietary intake of n-3 PUFAs1 
Dietary n-3 PUFA Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend 
ALA           
N(cases/total) 202/388 183/369 179/365 180/366   
median 0.21% 0.27% 0.32% 0.41%   
Model 1 1.00 0.89 (0.67, 1.18) 0.88 (0.65, 1.17) 0.90 (0.67, 1.19) 0.50 
Model 2 1.00 0.91 (0.67, 1.23) 0.97 (0.69, 1.36) 0.98 (0.68, 1.40) 0.99 
Model 3 1.00 0.99 (0.72, 1.36) 1.01 (0.71, 1.43) 1.02 (0.71, 1.49) 0.87 
EPA+DHA           
N(cases/total) 238/425 155/340 184/370 167/353   
median 0.09% 0.15% 0.20% 0.29%   
Model 1 1.00 0.63 (0.46, 0.85) 0.75 (0.57, 1.00) 0.67 (0.50, 0.90) 0.03 
Model 2 1.00 0.61 (0.45, 0.84) 0.70 (0.52, 0.95) 0.63 (0.46, 0.87) 0.02 
Model 3 1.00 0.64 (0.46, 0.88) 0.73 (0.53, 0.99) 0.64 (0.46, 0.89) 0.03 
1Values are odds ratio (95% CI) from conditional logistic regression. The fatty acids are expressed as % of total energy intake. Abbreviations: 
ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; EPA+DHA: sum of dietary EPA and DHA; DHA: docosahexaenoic acid; PUFA: 
polyunsaturated fatty acid. Model 1 was adjusted for total energy intake, age at recruitment, gender, father’s dialect, year of birth, year of 
recruitment, and year of blood collection. Model 2 was additionally adjusted for education, cigarette smoking, alcohol consumption, physical 


























Table 5-6. Odds ratios (95% CIs) of fatal and nonfatal myocardial infarction by quartiles of plasma n-3 PUFAs1 
Plasma n-3 PUFA N (cases/total) Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend 
ALA             
Fatal AMI 289/578 1.00 0.61 (0.35, 1.05) 0.37 (0.21, 0.67) 0.62 (0.34, 1.11) 0.14 
Nonfatal AMI 555/1110 1.00 0.86 (0.59, 1.25) 0.78 (0.52, 1.17) 0.80 (0.52, 1.24) 0.41 
EPA       
Fatal AMI 289/578 1.00 1.35 (0.76, 2.39) 0.86 (0.43, 1.74) 1.03 (0.50, 2.13) 0.78 
Nonfatal AMI 555/1110 1.00 0.93 (0.62, 1.38) 0.62 (0.40, 0.95) 0.58 (0.37, 0.91) 0.02 
DHA       
Fatal AMI 289/578 1.00 1.18 (0.69, 2.01) 1.06 (0.60, 1.88) 0.64 (0.28, 1.44) 0.25 
Nonfatal AMI 555/1110 1.00 0.75 (0.51, 1.11) 0.79 (0.53, 1.18) 0.59 (0.37, 0.96) 0.06 
1Values are odds ratio (95% CI). The fatty acids are expressed as % of total plasma fatty acids. Model was adjusted for total energy intake, age at 
blood collection, total plasma fatty acids, hours of fasting before blood collection, gender, father’s dialect, year of birth, year of recruitment, year 
of blood collection, education, cigarette smoking, alcohol consumption, physical activity, BMI, cholesterol intake, fiber intake, total fat intake, and 
history of hypertension and diabetes. Abbreviations: ALA: alpha-linolenic acid; AMI: acute myocardial infarction; EPA: eicosapentaenoic acid; 
DHA: docosahexaenoic acid; PUFA: polyunsaturated fatty acid. 
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The joint association of plasma long-chain n-3 PUFAs (EPA+DHA) and ALA 
with AMI is shown in Figure 5-1. As compared with participants who had lowest 
levels of both long-chain and intermediate-chain n-3 PUFAs, those with highest 
levels of both types of n-3 PUFAs had a 49% lower risk of AMI (OR=0.51, 95% 
CI: 0.31-0.84). The test for multiplicative interaction was not statistically 
significant (p=0.24). 
 
Figure 5-1. Risk of acute myocardial infarction according to join distribution 
of plasma EPA+DHA and ALA  
Model was adjusted for total energy intake, age at blood collection, total plasma fatty 
acids, hours of fasting before blood collection, gender, father’s dialect, year of birth, year 
of recruitment, and year of blood collection, education, cigarette smoking, alcohol 
consumption, physical activity, BMI, cholesterol intake, fiber intake, total fat intake, and 
history of hypertension and diabetes. Abbreviations: EPA: eicosapentaenoic acid; 
EPA+DHA: sum of plasma EPA and DHA; DHA: docosahexaenoic acid; ALA: alpha-
linolenic acid. 
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Table 5-7 shows the association between plasma n-3 PUFAs and AMI risk after 
further adjustment for various cardiovascular risk factors that could act as 
potential biological mediators. The association between ALA and AMI risk 
became significantly weaker after adjustment for LDL-cholesterol (OR 0.78, 95% 
CI 0.54-1.12) and significantly stronger after adjustment for HDL-cholesterol 
(OR 0.69; 95% CI 0.48-0.99). We thus estimated that LDL-cholesterol mediated 
19.9% of the association between ALA and AMI risk. Adjustment for 
cardiovascular risk factors did not significantly change the association between 
long-chain n-3 PUFAs and AMI risk. 
Table 5-7. Change in odds ratios (95% confidence intervals) of acute 
myocardial infarction comparing the highest versus lowest quartile of plasma 
n-3 PUFAs after addition of cardiovascular risk factors1 
  ALA EPA+DHA 
Models OR 95% CI Pmediation2 OR 95% CI Pmediation2 
Multivariable model3 0.73 (0.51, 1.05) 
 
0.62 (0.41, 0.94)  
add SBP 0.78 (0.54, 1.12) 0.17 0.61 (0.40, 0.94) 0.62 
add LDL-cholesterol 0.78 (0.54, 1.12) 0.04 0.58 (0.38, 0.89) 0.06 
add HDL-cholesterol 0.69 (0.48, 0.99) 0.04 0.66 (0.43, 1.00) 0.13 
add triglycerides 0.71 (0.49, 1.02) 0.26 0.63 (0.41, 0.96) 0.63 
add creatinine 0.72 (0.50, 1.04) 1.00 0.64 (0.42, 0.97) 0.89 
add C-reactive protein 0.73 (0.51, 1.06) 0.92 0.63 (0.41, 0.95) 0.48 
add HbA1c 0.75 (0.52, 1.08) 0.68 0.62 (0.41, 0.94) 0.53 
add all risk factors 0.78 (0.53, 1.15) 0.68 0.61 (0.39, 0.95) 0.83 
1Values are odds ratio (95% CI) from conditional logistic regression for the highest 
quartile against the lowest quartile. Number of missing values that were imputed: SBP: 
87; Triglycerides: 62; HbA1c: 2. Abbreviations: ALA: alpha-linolenic acid; EPA: 
eicosapentaenoic acid; EPA+DHA: sum of plasma EPA and DHA; DHA: 
docosahexaenoic acid; PUFA: polyunsaturated fatty acid; SBP: systolic blood pressure. 
2The statistical significance of the effect of addition of cardiovascular risk factors to the 
model (mediation effect) was tested using KHB method. 
3Multivariable model was adjusted for the variables listed in Model 3 of Table 5-4: total 
energy intake, age at blood collection, total plasma fatty acids, hours of fasting before 
blood collection, gender, father’s dialect, year of birth, year of recruitment, and year of 
blood collection, education, cigarette smoking, alcohol consumption, physical activity, 
BMI, cholesterol intake, fiber intake, total fat intake, and history of hypertension and 
diabetes. 
Chapter 5. Study III: Omega-3 fatty acids and AMI 
- 112 - 
 
Table 5-8 compares the association for long-chain n-3 PUFAs and AMI risk for 
different assessment methods (measured fatty acids versus dietary intakes) and 
different subtypes of AMI (fatal versus nonfatal). Associations for dietary long-
chain n-3 PUFAs intake and fish intake were similar to associations for the 
plasma long-chain n-3 PUFAs. We also integrated information from plasma and 
dietary long-chain n-3 PUFAs by taking the sum of their respective standardized 
z-scores. The integrated long-chain n-3 PUFA variable resulted in stronger 
associations with both fatal AMI (extreme-quartile OR=0.37, 95% CI: 0.19-0.72, 
P trend 0.002) and nonfatal AMI (extreme-quartile OR=0.61, 95% CI: 0.40-0.92, 
P trend 0.02). 
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Table 5-8. Odds ratios (95% confidence intervals) of total, fatal, and nonfatal acute myocardial infarction by quartiles of 
plasma and dietary long-chain n-3 PUFAs as well as fish consumption1 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend 
Plasma EPA+DHA2 
Total AMI 1.00 0.88 (0.63, 1.21) 0.87 (0.62, 1.23) 0.62 (0.41, 0.94) 0.03 
Fatal AMI 1.00 1.06 (0.61, 1.83) 1.24 (0.70, 2.20) 0.68 (0.31, 1.45) 0.33 
Nonfatal AMI 1.00 0.74 (0.50, 1.09) 0.79 (0.53, 1.18) 0.63 (0.39, 1.00) 0.10 
Dietary EPA+DHA3 
Total AMI 1.00 0.64 (0.46, 0.88) 0.73 (0.53, 0.99) 0.64 (0.46, 0.89) 0.03 
Fatal AMI 1.00 0.67 (0.38, 1.19) 0.59 (0.35, 0.99) 0.46 (0.26, 0.80) 0.006 
Nonfatal AMI 1.00 0.57 (0.39, 0.83)  0.68 (0.48, 0.98) 0.66 (0.45, 0.97) 0.12 
Dietary fish intake3 
Total AMI 1.00 0.83 (0.61, 1.14) 0.72 (0.52, 0.98) 0.68 (0.49, 0.95) 0.02 
Fatal AMI 1.00 1.05 (0.60, 1.85) 0.67 (0.40, 1.12) 0.55 (0.30, 0.99) 0.02 
Nonfatal AMI 1.00 0.60 (0.42, 0.88) 0.58 (0.40, 0.85) 0.60 (0.40, 0.89) 0.02 
Sum of standardized biomarker and intake2 
Total AMI 1.00 0.74 (0.54, 1.02) 0.62 (0.45, 0.85) 0.55 (0.38, 0.79) 0.001 
Fatal AMI 1.00 0.78 (0.46, 1.31) 0.55 (0.31, 0.96) 0.37 (0.19, 0.72) 0.002 
Nonfatal AMI 1.00 0.70 (0.48, 1.04) 0.61 (0.42, 0.88) 0.61 (0.40, 0.92) 0.02 
1Values are odds ratio (95% CI) from conditional logistic regression. The fatty acids are expressed as % of total fatty acids for the plasma 
biomarker, as % of total energy intake for dietary intake, and standard z-scores for the combined measure. Fish intake is expressed as grams per 
1000 kcal of total energy intake. N(cases/total) was 744/1488 in models for total AMI, 289/578 for fatal AMI, and 555/1110 for nonfatal AMI. 
Abbreviations: EPA: eicosapentaenoic acid; EPA+DHA: sum of EPA and DHA; DHA: docosahexaenoic acid; AMI: acute myocardial infarction. 
2Models were adjusted for total energy intake, age at blood collection, total plasma fatty acids, hours of fasting before blood collection, gender, 
father’s dialect, year of birth, year of recruitment, year of blood collection, education, cigarette smoking, alcohol consumption, physical activity, 
BMI, cholesterol intake, fiber intake, total fat intake, and history of hypertension and diabetes.  
3Models were adjusted for all variables listed in 2 except total plasma fatty acids and hours of fasting before blood collection, and were adjusted for 
age at recruitment instead of age at blood collection. 
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5.4 DISCUSSION 
In this prospective nested case control study of Singapore Chinese, higher 
circulating long-chain n-3 PUFAs (EPA and DHA) were associated with a lower 
incidence of AMI. For ALA, no clear trend was observed but the highest three 
quartiles were associated with a lower AMI risk as compared with the lowest 
quartile. The lowest risk was observed in participants with high plasma levels of 
both ALA and long-chain n-3 PUFAs, with no suggestion of weaker associations 
for ALA in persons with high levels of plasma long-chain n-3 PUFAs. Higher 
plasma ALA concentrations were associated with both more beneficial (lower 
LDL-cholesterol and lower blood pressure) and detrimental (lower HDL-
cholesterol and higher triglyceride concentrations) levels of cardiovascular risk 
factors. Results of our mediation analysis suggested that lower LDL-cholesterol 
concentrations may contribute to the association between ALA and a lower AMI 
risk, whereas lower HDL-cholesterol may weaken this association. Adjustment 
for cardiovascular risk factors did not substantially change the association 
between plasma long-chain n-3 PUFAs and AMI risk. Dietary long-chain n-3 
PUFAs intake and fish intake showed similar association with AMI risk as plasma 
long-chain n-3 PUFAs, and integrating information from plasma biomarker and 
dietary intake resulted in stronger associations with AMI risk. 
Our results are largely consistent with previous prospective studies which 
observed that consumption of EPA and DHA lowers risk of CHD (222). A recent 
meta-analysis of prospective and retrospective studies observed that dietary and 
circulating ALA was associated with a moderately lower risk of cardiovascular 
diseases with a pooled relative risk of 0.80 (95% CI: 0.63-1.03) and high and 
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unexplained heterogeneity (I2=79.8%) (247). Another meta-analysis of 
prospective studies on blood ALA levels also found a non-significantly lower risk 
of coronary heart disease with a pooled relative risk of 0.93 (95% CI: 0.83, 1.03) 
(30). The modest effect that we observed for plasma ALA on AMI risk is similar 
to these two meta-analyses. We also found a suggestion of a more pronounced 
association between ALA and fatal AMI than nonfatal AMI, consistent to those 
reported by several other cohort studies (25, 90) and a meta-analysis (248). We 
observed that higher plasma ALA was associated with better levels for some 
cardiovascular risk factors but worse levels for other risk factors. Possibly, the 
variation in the strength of the association between ALA and AMI risk in 
populations in previous studies depended on the relative importance of different 
cardiovascular risk factors for the development of AMI in that population.  
The observation that higher plasma ALA levels could further reduce AMI risk in 
the highest quartile of long-chain n-3 PUFAs corroborates the hypothesis that the 
two types of n-3 PUFAs affects the cardiovascular system independently. Indeed, 
although ALA could be converted to EPA and DHA, such endogenous 
biochemical conversion is limited in humans (249-251). This independent 
contribution was also observed in the same cohort on dietary intakes of n-3 
PUFAs and cardiovascular death (91). 
The subjects in our study generally have a high consumption of fish and other 
seafood (mean daily intake 54.7g ± 31.4g) which are the major contributors to 
EPA and DHA intakes (244). However, as many of the commonly consumed 
types of fish in Singapore are white lean fish, the plasma levels of EPA and DHA 
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in our study participants were not among the highest in the world (78, 223, 242, 
252). The observation that risk of AMI continued to decrease from the third 
quartile to the fourth quartile of the long-chain n-3 PUFAs suggested that there 
was no ceiling effect of these fatty acids in preventing AMI at the intake levels in 
our study population. In contrast, we did not observe a clear trend for the 
association between ALA and AMI risk with a suggestion that low intakes may 
increase risk, but that risk does not continue to decrease at higher levels of ALA 
intakes. A similar non-linear association was observed in a case-control study 
conducted in Costa Rica (25). 
N-3 PUFAs affect a wide range of physiological functions in multiple tissues. The 
associations between higher plasma EPA and DHA with both higher LDL- and 
HDL-cholesterol concentrations in our study are supported by meta-analyses of 
clinical trials (253, 254). Long-chain n-3 PUFAs have also been shown to lower 
plasma triglyceride concentrations and blood pressure in randomized trials (75, 
76). In contrast, we only observed a non-significant inverse association between 
EPA/DHA and blood pressure and a direct association between DHA and 
triglyceride concentrations. These non-typical observations might partly be 
explained by the lower intake of the n-3 PUFAs in our participants as compared 
with the higher dose tested in clinical trials of fish oils (76). Despite examining a 
wide range of cardiovascular risk factors, we did not observe substantial 
mediators of the inverse association of long-chain n-3 PUFAs with AMI risk. It is 
possible that putative beneficial effects of long-chain n-3 PUFAs are mediated 
through other pathways such as reduced platelet aggregation response (255), 
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reduced heart rate (256), and anti-arrhythmia (66). Furthermore, we observed that 
the strength of the association of fish consumption and AMI risk was simlar to the 
association of plasma EPA and DHA concentrations and AMI risk. It is possible 
that components of fish other than long-chain n-3 PUFAs, such as healthy protein, 
vitamin D and selenium, contribute to the association between fish consumption 
and a lower risk of AMI through mechanisms unrelated to effects observed in 
trials that provide fish oil in isolation (257). 
We observed an inverse association between ALA and blood pressure, and LDL-
and HDL-cholesterol concentrations, which is supported by the findings of 
several clinical trials (258-261). However, evidence for the effects of ALA on 
conventional cardiovascular risk factors has been mixed and controversial (94). 
The only meta-analysis of clinical trials on this topic found that ALA significantly 
decreases HDL-cholesterol, with no significant effects on blood pressure, LDL-
cholesterol, and triglycerides (262). However, the number of trials for some of the 
outcomes was small, and large heterogeneity in results existed for outcomes with 
larger number of trials. The type of control used, amount of intake, and duration 
of study could contribute to such variations in effects. Based on our observations 
in this present study, ALA may have both beneficial and detrimental effects on 
cardiovascular risk factors, which warrants further examination in other cohorts 
and clinical trials. 
The evaluation of self-reported dietary intakes and plasma fatty acid 
concentrations was highly complementary: self-reported intakes reflected more 
long-term habitual diet, while plasma assessment eliminated recall bias and 
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reflected the ‘internal dose’ of fatty acids that would have more 
pathophysiological impact on the development of AMI. In this study, we tried to 
reduce the misclassifications in either method by summing the standardized z-
scores of both measurements, and we observed stronger and more precise 
association than for either individual measurement. We also observed a 
significant inverse association with both fatal and nonfatal AMI, findings that 
might have been missed in the plasma biomarker analyses alone due to lower 
statistical power. We previously reported an association between higher ALA 
intakes and a lower risk of coronary heart disease death based on the entire cohort 
dataset of the Singapore Chinese Health Study (91). The lack of significant 
association between ALA intake and AMI risk in this nested case-control study 
may reflect limited statistical power due to the modest number of fatal AMI cases.  
Strengths of our nested case control study included the prospective design which 
reduces the likelihood of selection and recall bias. In addition, our use of 
validated food questionnaires and quantitative laboratory assays provided 
objective, specific and more accurate measures of exposures to n-3 PUFA. 
Furthermore, the analysis incorporating with a wide range of potential 
confounders and established cardiovascular risk factors minimized the potential 
founding bias on the observed n-3 PUFA-AMI risk associations. However, this 
study is also subject to several limitations. First, there might be some 
misclassification because of changes in dietary intakes over time. If this would be 
the case, the non-differential misclassification would result in an underestimate of 
true risk/protective effect of n-3 PUFAs on AMI risk. Second, as in any 
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observational study we cannot fully exclude the possibility of residual 
confounding factors due to dietary and lifestyle that were not well measured in 
our study. Third, mediation analyses might be under-powered to detect part of the 
mediation effects. Lastly, we suggest caution in generalizing the findings to other 
populations with a different ethnicity or substantially different intake levels. 
In conclusion, higher plasma levels of EPA and DHA were associated with lower 
risk of AMI in an ethnic Chinese population in Singapore. This association was 
largely independent of the established cardiovascular risk factors. Higher intakes 
of fish and long-chain n-3 PUFAs were similarly associated with a lower risk of 
AMI. These results suggest that higher fish consumption can contribute to a 
substantial reduction in the incidence of AMI. Furthermore, we observed the 
mediation effect of plasma ALA on established cardiovascular risk factors. 
Therefore, the ALA-AMI risk association could be dependent on prevalence and 
distribution of these ALA-related cardiovascular risk factors in the study 
population. This may explain the inconsistent findings in previous studies.
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CHAPTER 6. CONCLUSION 
6.1 SUMMARY OF FINDINGS 
The research upon which this thesis is based investigated the etiologic role and 
potential mediation pathways of dietary fatty acids in the development of 
coronary heart disease. 
In Study I, the effect of palm oil consumption on blood lipids was assessed by a 
systematic review of clinical trials with a meta-analysis. Palm oil consumption 
resulted in higher LDL-cholesterol than vegetable oils low in saturated fat, and 
higher HDL-cholesterol than trans-fat containing oils. Such effects of palm oil on 
blood lipids are as expected based on its high saturated fat content, which 
supports reduction of palm oil use by replacement with vegetable oils low in 
saturated fat and trans-fat. 
Studies II and III were based on a prospective case-control study of acute 
myocardial infarction (AMI) nested within a Chinese cohort residing in Singapore. 
Study II employed an automated clustering approach to group plasma fatty acids 
and oxylipins based on their inter-correlations. We observed that the risk of AMI 
was influenced by variations in plasma fatty acid composition: long-chain n-3 
fatty acids and stearic acid were inversely associated with AMI risk, while 
arachidonic acid was directly associated with AMI risk. Furthermore, the 
oxylipins we examined in this study do not seem to be key mediators of the fatty 
acids-AMI relation. A significant inverse association between thromboxane B2, an 
arachidonic acid derived oxylipin, and risk of AMI was observed which was 
unexpected and requires further study. 
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Study III examined the association between dietary and plasma biomarkers of 
plant- versus marine- based n-3 fatty acids and risk of AMI, and mediation by 
established cardiovascular risk factors. We observed an inverse association 
between plasma ALA and AMI risk, and this association became substantially 
weaker after adjustment for LDL-cholesterol and stronger after adjustment for 
HDL-cholesterol. Higher plasma alpha-linolenic acid (ALA) concentrations may 
have both beneficial (lower blood pressure, lower LDL-cholesterol) and 
detrimental effects (lower HDL-cholesterol, higher triglycerides) on 
cardiovascular risk factors. In contrast, plasma and dietary long-chain n-3 PUFAs 
were consistently and independently associated with a lower risk of AMI, and the 
cardiovascular risk factors did not seem to be significant mediators of this 
association. 
Collectively, our findings suggest important etiological involvement of dietary 
fatty acids in the development of coronary heart disease, the implications of 
which will be discussed next. 
 
6.2 IMPLICATIONS IN ETIOLOGY AND PUBLIC HEALTH 
Our findings from the meta-analysis Study I support limiting consumption of 
palm oil and replacing it with vegetable oils low in saturated fat and trans-fat. 
This provides important scientific evidence for policy-makers, particularly in 
regions where palm oil consumption is more prevalent. For example, an 
economic-epidemiologic model has been proposed, showing that a 20% excise 
taxation on palm oil purchases in India could possibly reduce cardiovascular 
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deaths by nearly half a million in 10 years (160). In Singapore, the recently 
launched Healthier Ingredient Scheme uses an economic lever to promote 
consumption of healthier unsaturated fat-based oils through subsidy (151). This 
marks an important step of translating scientific findings to nutritional policies. 
Cooking oil represents the major source of dietary fat in Singapore, and palm oil 
has been the most commonly used cooking oil for both home cooking and 
hawker-prepared food (109). This policy intervention of cooking oil choice has 
the potential to alleviate diet-related burden of cardiovascular diseases in the 
general Singapore population. 
In food preparations which require solid fats for their physical and sensory 
characteristics, natural saturated fat including palm oil may still be a healthier 
replacement for trans-fat in foods based on their different effects on blood lipids. 
It is interesting to note that not all saturated fatty acids are equally detrimental. As 
compared with the usual hypercholesterolemic saturated fatty acids with 12, 14 
and 16 carbons (lauric acid, myristic acid and palmitic acid respectively), the 18-
carbon stearic acid reduces blood LDL-cholesterol (225, 263). This non-
hypercholesterolemic effect of stearic acid was also supported by the results of 
our Study II. However, possibly due to high collinearity with the other 
cholesterol-raising saturated fatty acids, dietary and biomarker of stearic acid 
have been observed to be associated with increased CHD risk in most previous 
studies conducted in western populations. Our Asian study participants whose 
plasma stearic acid levels were only weakly correlated with other saturated fatty 
acids provided a unique opportunity to examine the individual effect of stearic 
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acid. Our observation that plasma stearic acid was inversely associated with AMI 
risk warrants further study on the cardiovascular effects of dietary stearic acid 
independent from the effects of other saturated fat. Our results, if confirmed, may 
suggest important strategies of trans-fat replacement in the food industry by 
stearic acid-rich oils such as shea butter (67). 
After a thorough examination of self-reported intake as well as plasma biomarkers 
in Study II and III, long-chain n-3 fatty acids were consistently associated with a 
lower cardiovascular risk, and this association was similar to that for fish 
consumption. Our findings thus support adequate intake of long-chain n-3 fatty 
acids from marine products in this Asian population. According to 
recommendations from the American Heart Association, people should consume 
0.5-1.8 grams of EPA and DHA per day, or at least 2 servings of fish per week, to 
enjoy a significantly reduced risk of cardiovascular mortality (68). In our study, 
the median of the study subjects in the highest quartile consumes 0.3% of total 
energy from n-3 fatty acids, or 84 g/day of fish. Based on a 2000 kcal/day diet, 
this is equivalent to 0.67 g/day of EPA and DHA intake, and approximately 1 
serving/day of fish intake. The reason why such relatively high frequency of fish 
consumption does not result in equally high intake levels of n-3 fatty acids is 
probably because in Singaporean diet white lean fish is more commonly 
consumed than fatty fish. While it is reassuring to see that even lean fish 
consumption confers cardiovascular benefits in this population (highest versus 
lowest quartile: 45% reduced risk of fatal AMI and 40% reduced risk of nonfatal 
AMI), more fatty fish consumption, including salmon, tuna, sardine, and mackerel, 
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should be encouraged to benefit from higher intake of long-chain n-3 fatty acids. 
In addition, more healthful ways of cooking, including boiling, steaming, and 
baking, should be encouraged when preparing fish dishes, as frying or canning 
processes could result in significant losses of long-chain n-3 fatty acids in fatty 
fish (264). 
The efficacy of alpha-linolenic acid (ALA) in CHD prevention is of great 
importance especially in regions where fish availability is limited. Findings from 
study III support a moderate cardio-protective role of ALA in this Singapore 
Chinese population, particularly with the prevention of fatal AMI. Furthermore, 
higher ALA intake could provide additional cardiovascular benefits for people 
who consume sufficient fish fatty acids. Our study thus supports adequate intake 
of both long-chain n-3 fatty acids from fish and ALA from nuts, seeds and 
vegetable oils.  
As a summary of the etiological mediation mechanisms explored in this thesis, 
lower HbA1c might partially mediate the inverse association of stearic acid with 
AMI risk; and lower LDL-cholesterol may be one of the mechanisms accounting 
for the inverse association between ALA and risk of AMI. Nevertheless, a large 
proportion of the associations for plasma fatty acids and AMI risk could not be 
explained by the cardiovascular risk factors we examined, and these associations 
were largely independent of the oxylipins that we measured. Future studies are 
warranted to explore other possible biological mechanisms mediating the 
influences of fatty acids. 
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6.3 LIMITATIONS 
There are also several potential limitations that need to be considered in the 
interpretation of our findings.  
Meta-analysis of clinical trials is usually considered as the strongest evidence for 
the effect of exposures on health outcomes. Yet, our meta-analysis could be 
subject to various biases, including publication bias, and biases introduced by 
inclusion of trials poorly designed or conducted. To minimize the influence of 
such potential biases, we have conducted thorough subgroup analysis by study 
size, study design, and study quality. After exclusion of non-randomized trials and 
with consideration of the test oil dose and comparison oil type, our major study 
findings persisted with only modest heterogeneity and no suggestion of 
publication bias. Another limitation of this meta-analysis is that we considered 
intermediary markers of CHD instead of disease outcomes. Findings from the 
only population study to-date which evaluated the direct association between 
palm oil consumption and CHD were consistent with our estimates on blood lipid 
changes. Future prospective examination of palm oil consumption in relation to 
CHD events is needed to confirm the observations in that study. 
Our nested case-control study of AMI was less prone to selection and recall biases 
as a result of its prospective design. Yet, the dietary assessment and blood 
biomarker analysis could still be subject to measurement error and 
misclassification. Such misclassification is likely to be non-differential since the 
collection of dietary information and blood samples was before disease outcome 
occurred, and thus may lead to attenuated associations. The single time-point 
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measurement of plasma fatty acids may not well represent long-term dietary 
intakes because plasma fatty acids composition could be affected by dietary 
changes in a few weeks (265). The use of food frequency questionnaire could 
complement part of this limitation by asking the habitual diet of study participants 
in the past year.  
As compared with self-reported intakes, biochemical markers of fatty acids 
provide a more objective assessment, but these measured concentrations are 
subject to both exogenous dietary factors and endogenous metabolic processes. 
Thus, it is difficult to attribute the observed variations in fatty acid biomarkers to 
dietary, genetic or metabolic influences. Therefore, caution should be exercised 
when generalizing observations from such biomarker studies to dietary advice, as 
in the case of stearic acid in study II. 
As in all observational studies, another limitation of this study was possible 
residual confounding by other dietary and lifestyle factors which were not 
measured or incompletely adjusted for. The external validity, or the extent to 
which the study results can be generalized to other populations or other intake 
levels, should also be carefully considered. Therefore, conclusion on causality 
should not be made from a single observational epidemiologic study, but rather be 
based on a consensus of a large body of evidence from different study designs and 
different populations.  
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6.4 FUTURE PERSPECTIVES 
Abundant evidence has shown that specific dietary fatty acids play a role in the 
development of CHD. However, the dose-response relationships between specific 
fatty acids intake and CHD risk are not well defined. Further epidemiologic 
studies in different populations with different intake ranges will be useful to 
derive the optimal intakes of various fatty acids. For instance, ALA appeared to 
be non-linearly related to risk of AMI in our study with a relatively low threshold 
of plateau. Similar non-linear association was observed in another study on 
adipose tissue ALA, but with a different threshold level (25). It is hence important 
to evaluate the dose-relationship between ALA and CHD using large datasets 
such as pooled data from a large number of observational and interventional 
studies in different populations. To give another example, polyunsaturated fat 
intake appeared to be linearly associated with lower CHD rates within the range 
of up to 8% of energy (266). A much higher level of intake is feasible (267), but 
the relation with CHD in this range remains to be elucidated.  
Our observations about stearic acid and ALA warrant future studies examining 
the fatty acids and CHD relationship in non-western populations. Diets in 
different populations have different food sources and intake ranges of various 
fatty acids (108, 109). Studies in the under-reported non-western populations 
provide an opportunity to examine the fatty acids in different ranges as well as to 
separate the effects of highly correlated fatty acids in western diet. In addition, the 
association between fatty acids and CHD risk may vary across different study 
populations depending on the relative importance of different cardiovascular risk 
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mechanisms. Future research to identify the group of risk factors relevant to 
specific populations could be useful in providing tailored dietary advice. 
Many hypotheses based on animal studies and theoretical mechanisms that relate 
specific fatty acids to risk factors and clinical endpoints remain to be investigated 
in human populations. In the example of long-chain n-3 fatty acids, we did not 
identify significant mediators of their beneficial effects through influences on 
blood lipids, blood pressure, inflammation, or generation of oxylipins. Future 
studies examining other potential mechanisms in population-based studies are 
hence warranted, e.g. reduced susceptibility to ventricular arrhythmia, reduced 
thrombosis, decreased growth of atherosclerotic plaques, reduced heart rate, and 
improved endothelial function (68).  
In addition, aspects of nutrition other than types of fat could also influence 
cardiovascular health through various mechanisms. For example, strong evidence 
suggests that moderate alcohol intake (268), higher intakes of fruits, vegetables, 
and nuts (269) could reduce the risk of CHD. Carbohydrate quality also appears to 
be important in that replacement of refined carbohydrates and added sugars by 
whole grains rich in fiber and low in glycemic index could possibly reduce CHD 
risk (269). Fish, poultry, nuts or dairy products seem to be healthier protein 
sources than red meat with respect to cardiovascular risk (270). Therefore, besides 
evaluation of individual nutrients or foods, dietary recommendations regarding 
the optimal intake of fatty acids should be given as part of achieving an overall 
healthier dietary pattern. 
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In summary, findings of this thesis provide significant support for etiology study 
of the relationship between fatty acids and risk of CHD as well as support for 
potential dietary advice and policy-making. Our research, in combination with 
previous studies, supports a higher intake of n-3 polyunsaturated fatty acids and 
replacement of palm oil with low saturated fat vegetable oils. Yet, our findings 
also highlight that the mechanisms underlying associations between fatty acids 
and CHD risk are not completely understood yet and requires further study. We 
anticipate a deeper and more complete understanding of the role of dietary fatty 
acids in the etiology of CHD in the near future, which could be applied to 
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